 
Protocol KP 415.E01 Amendment #[ADDRESS_1247516] a need to know, with the obligation not to further disseminate 
this information . 
 
 
  April 6, 2018  
  
A Multicenter, Dose -Optimized, Double -Blind, 
Randomized, Placebo -Controlled, Parallel Efficacy 
Laboratory Classroom Study with KP415 in Children 
with Attention -Deficit/Hyperactivity Disorde r 
 
 
 
 
Protocol No:  KP415.E01 
Original Protocol Date: August 04, 2017  
Amendment #1: November 13, 2017  
Amendment #2: April 0 6, 2018  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol KP415.E01 Amendment #[ADDRESS_1247517] OF ABBREVIATIONS  ................................ ................................ ................................ ...6 
PROTOCOL SYNOPSIS  ................................ ................................ ................................ .......... 8 
1. SCHEDULE  OF EVENTS  ................................ ................................ ..............................  23 
2. STUDY DESIGN SCHEMATIC  ................................ ................................ ....................  27 
3. BACKGROUND ................................ ................................ ................................ ..............  28 
3.1. Attention -Deficit Hyperactivity Disorder (ADHD)  ................................ ....................  28 
3.2. Laboratory Classroom Studies  ................................ ................................ ...................  28 
4. KP415: A PRODRUG CONJUGATE  ................................ ................................ ............  [ADDRESS_1247518] SELECTION  ................................ ................................ ................................ . 32 
9.1. Number of Subjects  ................................ ................................ ................................ ... 32 
9.2. Study Population  ................................ ................................ ................................ ....... 33 
9.2.1.  Inclusion Criteria (at Screening, except when noted otherwise)  ................................ .........  33 
9.2.2.  Exclusion Criteria (at Screening, except when noted otherwise)  ................................ ........  34 
9.2.3.  Eligibility Criteria (End of Dose Optimization Phase)  ................................ .......................  38 
9.2.4.  Rescreening  ................................ ................................ ................................ ......................  38 
10. STUDY TREATMENTS  ................................ ................................ .............................  38 
10.1.  KP415 Dose Optimization  ................................ ................................ .........................  38 
10.2.  Study Drug Administration in the Double -Blind Treatment Phase  ..............................  39 
10.3.  Treatment Assignment/ Randomization  ................................ ................................ ...... 39 
10.4.  Blinding  ................................ ................................ ................................ .....................  40 
10.5.  Compliance  ................................ ................................ ................................ ...............  40 
11. STUDY PROCEDURES  ................................ ................................ .............................  40 
11.1.  Screening Procedures  ................................ ................................ ................................ . 41 
11.2.  Open -Label Dose Optimization Phase (Visit 2 -5)................................ .......................  43 
11.2.1.  Visit 2 (Day 0) ................................ ................................ ................................ ..............  43 
11.2.2.  Visit 3 (Day 7 ±3 days)  ................................ ................................ ................................ . 44 
11.2.3.  Visit 4 (Day 14 ±3 days)  ................................ ................................ ...............................  45 
11.2.4.  Visit 5 (Day 21 ±3 days)  ................................ ................................ ...............................  47 
11.2.5.  Unscheduled Visits  ................................ ................................ ................................ ....... 49 
11.3.  Treatment Phase: Days 22 -27 & Visit 6 (Day 28)  ................................ ......................  50 
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 4 of 81  April 6, 2018  
 11.4.  Early Termination Visit  ................................ ................................ .............................  51 
11.5.  Follow -Up Visit  ................................ ................................ ................................ .........  52 
11.6.  End of Study (EOS)  ................................ ................................ ................................ ... [ADDRESS_1247519]  ................................ ................................ .............  55 
13.1.  Active Pharmaceutical Ingredients  ................................ ................................ .............  55 
13.2.  Clinical Trial Material  ................................ ................................ ...............................  55 
13.3.  Pharmaceutical Formulation  ................................ ................................ ......................  56 
13.4.  Packaging and Labeling  ................................ ................................ .............................  56 
13.4.1.  Open -Label Dose Optimization Phase ................................ ................................ ...........  56 
13.4.2.  Double -Blind Treatment Phase  ................................ ................................ .....................  56 
13.5.  Dispensing Procedures  ................................ ................................ ...............................  57 
13.5.1.  Open -Label Dose Optimization Phase ................................ ................................ ...........  57 
13.5.2.  Double -Blind Treatment Phase  ................................ ................................ .....................  57 
13.6.  Storage of Study Drug  ................................ ................................ ...............................  58 
13.7.  Study Drug Accountability  ................................ ................................ ........................  59 
14. SAFETY AND EFFICACY ASSESSMENTS  ................................ ............................  59 
14.1.  Medical History  ................................ ................................ ................................ .........  59 
14.2.  Physical Examination  ................................ ................................ ................................  59 
14.3.  ADHD Diagnosis and Severity Assessments  ................................ ..............................  59 
14.4.  Columbia -Suicide Severity Rating Scale (C -SSRS)  ................................ ...................  [ADDRESS_1247520]  ................................ ................................ ................................ ..........  63 
14.9.  Adverse Event Assessments  ................................ ................................ .......................  63 
15. DISCONTINUATION AND REPLACEMENT OF SUBJECTS  ..............................  64 
15.1.  Withdrawal of Subjects from the Study  ................................ ................................ ...... 64 
15.2.  Replacement of Subjects  ................................ ................................ ............................  64 
16. EFFICACY ENDPOINTS  ................................ ................................ ...........................  64 
16.1.  Primary Efficacy Variable:  ................................ ................................ ........................  65 
16.2.  Secondary Efficacy Variables:  ................................ ................................ ...................  65 
16.3.  Safety Endpoints:  ................................ ................................ ................................ ....... 65 
17. STATISTICAL CONSIDERATIONS  ................................ ................................ ........  65 
17.1.  Statistical Hypotheses  ................................ ................................ ................................  65 
17.1.1.  Primary Efficacy Endpoint(s):  ................................ ................................ ......................  65 
17.1.2.  Secondary Efficacy Endpoints  ................................ ................................ ......................  66 
17.2.  Sample Size Calculation  ................................ ................................ ............................  66 
17.3.  Populations for Analysis  ................................ ................................ ............................  69 
17.4.  Statistical Analyses  ................................ ................................ ................................ .... 69 
17.4.1.  General Approach  ................................ ................................ ................................ ........  69 
17.4.2.  Analysis of the Primary Efficacy Endpoint  ................................ ................................ ... 70 
17.4.3.  Analysis of the Secondary Endpoints  ................................ ................................ ............  70 
Protocol KP415.E01 Amendment #[ADDRESS_1247521] Keepi[INVESTIGATOR_007]  ................................ ................................ ................................ .........  78 
21.3.  Access to Source Data/Documents  ................................ ................................ .............  78 
22. QUALITY CONTROL AND QUALITY ASSURANCE  ................................ ...........  78 
23. ETHICS AND GOOD CLINICAL PRACTICE COMPLIANCE  ............................  79 
24. INSURANCE  ................................ ................................ ................................ ...............  79 
24.1.  Insurance Compensation  ................................ ................................ ............................  79 
25. COMPLETION OF STUDY  ................................ ................................ .......................  79 
26. STUDY ADMINISTRATIVE INFORMATION  ................................ ........................  79 
26.1.  Protocol Amendments  ................................ ................................ ................................  79 
27. REFERENCES  ................................ ................................ ................................ ............  80 
 
  
Protocol KP415.E01 Amendment #[ADDRESS_1247522]  Aspartate transaminase  
AUC  Area under the plasma concentration -time curve  
β-hCG  Beta human chorionic gonadotropin  
BLQ  Below the limit of quantification  
BMI  Body Mass Index  
CBT  Cognitive Behavioral Therapy  
CDC  Centers for Dise ase Control and Prevention  
CFR  Code of Federal Regulation s 
CGI-S Clinical Global Impressions –Severit y 
CGI-I Clinical Global Impressions –Improvement  
CI Confidence I nterval  
Cmax Maximum observed plasma concentration  
CNS  Central nervous system  
CRO  Contract Research Organization  
C-SSRS  Columbia -Suicide Severity Rating Scale  
CTCAE  Common Terminology Criteria for Adverse Events  
CV Coefficient of V ariation  
DMDD  Disruptive Mood Dysregulation Disorder  
DSM -[ADDRESS_1247523]  
ITT Intent -to-Treat  
Protocol KP415.E01 Amendment #[ADDRESS_1247524]  
PK Pharmacokinetic  
PP Per-Protocol  
PT Prothrombin Time  
PTT Partial Thromboplastin Time  
Q1 25th Percentile (1st Quartile)  
Q3 75th Percentile (3rd Quartile)  
QTcF Time between the start of the  Q wave  and the end of the  T wave  (QT interval) in 
the heart's  electrical cycle, corrected for heart rate with Fridericias’s formula  
RS Randomized Safety  
SAE  Serious Adverse Event 
SAP Statistical Analysis Plan  
SKAMP  Swanson, Kotkin, Agler, M -Flynn, and Pelham  Rating Scale  
SKAMP -A SKAMP -Attention  
SKAMP -C SKAMP -Combined  
SKAMP -D SKAMP -Deportment  
SOE  Schedule of Events  
SNRI  Serotonin Norepi[INVESTIGATOR_584872] I nhibitor  
SSRI  Selective Serotonin Reuptake I nhibitor  
SW Shapi[INVESTIGATOR_2152] -Wilk  
T1/[ADDRESS_1247525]  Upper Limit of Normal  
WREMB -R Weekly Rating of Evening and Morning Behavior - Revised  
Tmax Time to achieve the maximum observed plasma concentration  
  
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 8 of 81  April 6, 2018  
 PROTOCOL SYNOPSIS  
TITLE  A Multicenter, Dose -Optimized, Double -Blind, Randomized, 
Placebo -Controlled, Parallel Efficacy Laboratory Classroom 
Study with KP415 in Children with Attention -
Deficit/Hyperactivity Disor der 
SPONSOR  KemPharm, Inc.  
PROTOCOL NUMBER  KP415.E01  
INVESTIGATIONAL 
PRODUCT  KP415  (a prodrug of d -methylphenidate, d -MPH)  
NAME [CONTACT_728321]415 prodrug is 3-(((S) -1-
carboxy -2-hydroxyethyl)carbamoyl) -1-((((R)-2-((R)-2-
methoxy -2-oxo-1-phenylethyl)pi[INVESTIGATOR_119510] -1-
carbonyl)oxy)methyl) pyridine -1-ium chl oride  (single d -
methylphenidate  molecule covalently attached via a 
carbamate bond to a methylene oxide linker which in turn is 
connected to the nitrogen of the pyridine ring of a nicotinoyl -
serine moiety ). 
ROUTE  Oral 
NUMBER OF SITES  5 sites in the United  States of America  
STUDY DESIGN  The study is a multicenter, dose -optimized, double -blind, 
randomized, placebo -controlled, parallel efficacy laboratory 
classroom study with KP415 in children with Attention -
Deficit/Hyperactivity Disorder (ADHD). The study will 
consist of a Screening Period, an Open -Label Dose 
Optimization Phase, a Double -Blind Treatment Phase and a 
Follow -Up Visit, as follows:  
• Screening Period:  Subjects will undergo a screening 
period up to 49 days prior to entering into the Open -
Label Dose  Optimization Phase.  
• Open -Label Dose Optimization Phase:  During the 
Dose Optimization Phase, subjects will be titrated to 
doses of 20, [ADDRESS_1247526] individual dose -response in the opi[INVESTIGATOR_684].  
• Double -Blind Treatment Phase:  Eligible subjects 
will be randomized to receive  single daily doses of 
KP415 or Placebo for [ADDRESS_1247527] 
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 9 of 81  April 6, 2018  
 dose of th e Treatment Period.  
• Follow -Up Visit:  3 ±[ADDRESS_1247528] dose of the Treatment Phase, subjects will enter a 
Follow -Up Visit to evaluate safety parameters.  
PRIMARY OBJECTIVE  To determine the efficacy of KP415 compared to placebo in 
treating children 6 -12 years old with ADHD in a laboratory 
classroom setting . 
SECONDARY 
OBJECTIVES  • To determine the onset and duration of the clinical 
effect of KP415 in treating ADHD in children 6 -12 
years old in a laboratory classroom setting.  
• To determine the safety and tolerability of KP415 
compared to placebo in treating children [ADDRESS_1247529] SELECTION  
CRITERIA  Inclusion Criteria  (at Screening , except when noted 
otherwise ) 
1. Subject must be at least 6 years old and less than 13 
years old at the start of the Dose Optimization Phase 
(Day 0) . 
2. Subject must have a b ody weight of at least [ADDRESS_1247530] 
dose of study drug h as been taken. Childbearing 
potential is defined as follows: Girls under the age of 
[ADDRESS_1247531] period will be 
considered “not of child -bearing potential”. Girls of 12 
years and older (including girls who will become 12 
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 10 of 81  April 6, 2018  
 years or older d uring the study) will be considered “of 
child -bearing potential”, even if they have not yet had 
their first period. Irrespective of age, girls who have 
had their first period, will be considered “of child -
bearing potential”.  
4. Subject must be in general good  health defined as the 
absence of any clinically relevant abnormalities as 
determined by [CONTACT_728287], vital signs, ECGs, 
medical history, and clinical laboratory values 
(hematology, chemistry  and urinaly sis) at Screening. 
If any of the hematology, chemistry, or urinalysis 
results are not within the laboratory's reference range, 
then the subject can be included only if the 
Investigator determines the deviations to be not 
clinically relevant.  
5. At least one p arent/legal guardian of the subject must 
voluntary give written permission  for him/her to 
participate in the study.  
6. Subject must give written or verbal assent  prior to 
study participation.  For verbal assent, t he procedure 
will be documented and signed by a witness. A parent 
or guardian may not be the witness for a child's 
verbal assent document.  
7. Subject must meet Diagnostic and Statistical Manual 
of Mental Disorders - Fifth Edition (DSM -5) criteria 
for a primary diagnosis of ADHD (combined, 
inattentive, or hyperactive/impulsive presentation) 
per clinical evaluation and confirmed by [CONTACT_891167] (MINI -KID).  
8. Subject must have a score of at least 3 (mildly ill) on 
the clinician -administered Clinical Global 
Impressions –Severity (CGI -S) scale.  For subjects 
requiring washout of ADHD medications, this 
criterion refers to a score following washout . 
9. Subject must be a ble and willing to w ash out current 
stimulant ADHD medications, including herbal 
medications  from 5 days prior to the start of the Dose 
Optimization Phase (Day 0) , and abstain from taking 
these  to the end of the Follow -Up Visit or Early 
Termination ; and wash out non -stimulant  ADHD 
medications from 21 days prior to the start of the 
Dose Optimization Phase (Day 0), and abstain from 
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 11 of 81  April 6, 2018  
 taking these to the end of the Follow -Up Visit or 
Early  Termination . 
10. An ADHD -Rating Scale -5 (ADHD -RS-5) total score 
(DuPaul et al. 2016 ) of at least 28 at Visit 2 ( Day 0 ). 
For subjects  requiring washout of ADHD 
medications, this criterion refers to a score following 
washout.  
11. Subjects need to be able to perform at least the basic 
level of problems on  the PERMP , based on a 
calibration assessment  (Placeme nt PERMP) 
performed at Visit 2  (Day 0) . 
12. Subject, subject’s parent/legal guardian and caregiver 
(if applicable ) must understand and be willing and 
able to comply with all study procedures and visit 
schedule. If the subject is cared for by a caregiver for 
relevant parts of a school day, and if in this case, in 
the opi[INVESTIGATOR_689], the caregiver of the 
subject is more suitable for certain assessments (for 
example, Con ners 3-P and WREMB -R), the caregiver 
will need to agree to the applicable proced ures and 
visits.  
13. Subject , parent/ legal guardian  and caregiver  (if 
applicable) must be able to speak and understand 
English, and be able to communicate satisfactorily 
with the Investigator and study coordinator.  
14. Subject must be able to swallow size 3 capsul es as 
demonstrated by [CONTACT_891168] a size 3 capsule at 
Screening.  
Exclusion Criteria  (at Screening , except when noted 
otherwise ) 
1. If female, must not be pregnant or breastfeeding, and 
if of childbearing potential,  must have a negative 
serum pregnancy t est at Screening.  In addition, a  
positive pregnancy test before the last dose of study 
drug will exclude a subject from further participation 
in the study . “Of childbearing potential” is defined in 
Section 14.8.  
2. Subject with any clinically significant chronic 
medical condition that, in the judgment of the 
Investigator, may interfere with the participant's 
ability to participate in the study.  
3. Subject has any diagnosis of bipolar I or II disorder, 
major depressive disorder, conduct disorder, 
obsessive -compulsive disorder, any history of 
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 12 of 81  April 6, 2018  
 psychosis, autism spectrum disorder, disruptive mood 
dysregulation disorder (DMDD), intellectual 
disability, Tourette's Syndrome, confirmed genetic 
disorder with cognitive and/or behavioral 
disturbances. Subjects with oppos itional defiant 
disorder (ODD) are permitted to enroll in the study as 
long as ODD is not the primary focus of treatment, 
and, in the opi[INVESTIGATOR_689], the ODD is 
mild to moderate, and eligible subjects with ODD are 
appropriate and cooperative d uring Screening . 
4. Subject has generalized anxiety disorder or panic 
disorder that has been the primary focus of treatment 
at any time during the [ADDRESS_1247532] has evidence of any chronic disease of the 
central nervous system (CNS) such as tumors, 
inflammation, seizure disorder, vascular disorder, 
potential CNS related disorders that might occur in 
childhood (e.g., Duchenne Muscular dystrophy, 
myasthen ia gravis, or other neurologic or serious 
neuromuscular disorders), or history of persistent 
neurological symptoms attributable to serious head 
injury. A past history of febrile seizure , drug -induced 
seizure, or alcohol withdrawal seizure  is allowed . 
Subject taking anticonvulsants for seizure control 
currently or within the past [ADDRESS_1247533] has a c urrent (last month) psychiatric 
diagnosis other than specific phobia, motor skills 
disorders, oppositional defiant disorder, sleep 
disorders, elimination disorders, adjustment 
disorders, learning disorders, or communication 
disorders. Participants with school phobia or 
separation anxiety will not be eligible.  Subjects 
allowed to enroll with any of these DSM disorders 
will require written justification from the Investigator 
documenting why the conditions will not interfere 
with participation and to emphasize that ADHD is the 
primary indication.  
7. Subject has any history of attempted suicide or 
clinical ly significant suicidal ideation  based on the C -
SSRS assessment, in the opi[INVESTIGATOR_689], at 
Screening or at any time before the last dose of study 
drug.  
Protocol KP415.E01 Amendment #[ADDRESS_1247534] has any clinically significant unstable 
medical abnormality, chronic disease, or a history of 
a clinically significant abnormality of the 
cardiovascular (including cardiomyopathy, serious 
arrhythmias, structural cardiac disorders, or severe 
hypertension), gastrointestinal, respi[INVESTIGATOR_696], hepatic, 
or renal systems, or a disorder or history of a 
condition (e.g., malabsorption, gastrointestinal 
surgery) that may interfere with drug absorption, 
distribution, metabolism, or excretion of study drug. 
Active medical conditions that are minor or well -
controlled are not exclusionary if they do not af fect 
risk to the subject or the study results. In cases in 
which the impact of the condition upon risk to the 
subject or study results is unclear, the medical 
monitor should be consulted. Any subject with a 
known cardiovascular disease or condition (even i f 
controlled) must be discussed with the medical 
monitor during Screening.  
9. Subject has a history or presence of abnormal ECGs, 
which in the Investigator's opi[INVESTIGATOR_455992]. Screening site ECGs will be centrally 
over-read, and eligibility w ill be determined by [CONTACT_891169] -read 
report.  
10. Subject has a history of, or currently has a 
malignancy, except for non -melanomatous skin 
cancer.  
11. Subject has uncontrolled thyroid disorder as 
evidenced by [CONTACT_891170] (TSH) 
≤0.8 x the lower limit of normal (LLN) or ≥1.25 x the 
upper limit of normal (ULN) for the reference 
laboratory at Screening.  
12. Subjects  with a history of substance abuse or 
treatment (including alcohol) within [ADDRESS_1247535] is willing to wash 
out the current medication as required.  
Protocol KP415.E01 Amendment #[ADDRESS_1247536] has a positive urine methylphenidate screen 
at the sta rt of the Dose Optimization Phase (Day 0 , 
Visit 2 ). 
15. Subject who has initiated  Cognitive Behavioral 
Therapy (CBT) for the treatment of ADHD  less than 
1 month prior to Screening  (subjects on stable CBT 
will be allowed) , has initiated behavioral therapy 
(including school based interventions)  less than [ADDRESS_1247537] has participated in a classroom study within 6 
months prior to the start of Screening, or has 
participated in any other clinical study with an 
investigational drug/product within [ADDRESS_1247538] , parent/legal guardian  and caregiver (if 
applicable at the Investigator’s discretion) has 
Protocol KP415.E01 Amendment #[ADDRESS_1247539]'s family anticipates a move outside 
the geographic range of the investigative site during 
the study period, or plans extended travel inconsistent 
with the recommended visit interval during study 
duration . 
26. Subject's parent/legal guardian is an investigational 
site staff member or a relative of an investigational 
site staff member.  
27. Subjects with a family member living in the same 
household participating in another ADHD clinical 
trial during the period of Screening through the 
Follow -Up Visit will be excluded. Subjects with a 
family member living in the same household 
participating in the current c linical trial during the 
administration of study drug (Visits 2 to 6)  will be 
excluded. Different subjects from the same family are 
allowed in this trial if they are in different cohorts, 
and there is no overlap in time from Visit [ADDRESS_1247540] to participate in this 
study.  
Eligibility Criteria (End of Dose Optimization Phase)  
Subjects will need to meet the following additional eligibility 
criteria at the end of the Dose Optimizatio n Phase in order to 
enter into the Double -Blind Treatment Phase:  
1. A reduction of  ≥30% reduction of ADHD -RS-5 from 
baseline (Day 0) during the Open-Label Dose 
Optimization Phase.  
2. A CGI-I score of 1 or 2 points (“Very Much 
Improved” or “Much Improved”) at the  end of  the 
Open-Label Dose Optimization Phase.  
3. Acceptable tolerability of the optimized KP415  dose 
experienced during the Dose Optimization Phase.  
These assessments will be made based on the days before 
Visit 5 while still taking study drug (and NOT based  on the 
2 days of no study drug before Visit 5) . 
Rescreening  
Subjects who are screened outside the screening window may 
be rescreened for participation in a later cohort. Subjects who 
received any dose of study drug and are terminated early or 
are not elig ible to continue in the Treatment Phase, are not 
eligible to participate in another cohort of the study (and will 
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 16 of 81  April 6, 2018  
 not be rescreened).  
TEST PRODUCT, DOSE, 
AND ROUTE OF 
ADMINISTRATION  The KP415 capsules  contain two active pharmaceutical 
ingredients: d -methy lphenidate (d -MPH) hydrochloride as the 
immediate release (IR) d -MPH component, and KP415 
prodrug as the extended release (ER) d -MPH component. In 
terms of d -MPH equivalent amounts, all capsule strengths 
contain 30% of d -MPH (IR component) and 70% of d -MPH  
from the KP415 prodrug  (ER component) . The total 
equivalent amount of d -MPH in each capsule strength (used 
as daily doses in this study), and the amounts of both APIs are 
listed in the following table.  
Total  
d-MPH 
dose 1 
(mg)  d-MPH  2 
 
 
(mg)  KP415  
Prodrug 3 
 
(mg)  
20 6 28 (14) 
30 9 42 (21)  
40 12 56 (28)  
1. Based on the d -MPH amount plus the equivalent amount of d -MPH as 
KP415 prodrug.  
2. The dose of d -MPH is expressed in terms of d -methylphenidate 
hydrochloride . 
3. The dose of KP415 prodrug is expressed in terms of KP415 chloride . 
The amount of d-MPH  hydrochloride  equimolar to each KP415 
prodrug dose  is listed between parentheses.  
 
In the Open -Label Dose Optimization Phase, daily treatments 
of 20, 30 and 40 mg open -label KP415 capsules will be 
administered  (one ca psule/day), for the titration to an optimal 
daily KP415 dose.  At Visits [ADDRESS_1247541] not take  study drug  (this is 
important for obtaining a baseline of the SKAMP/PERMP 
scores) . On the other days of the Dose Optimization Phase, 
the medication will be taken in the morning at home . The 
dose taken at the school site at Visit [ADDRESS_1247542] dose of  
unblinded  study drug.  
 
In the Double -Blind Treatment Phase, t he following 
treatments will be administered:  
• Treatment A: one KP415 capsule (test product) once daily 
for 7 days.  
• Treatment B: one m atching placebo capsule once daily for 
7 days.  
The daily dose of KP415 in the Treatment Phase will be same  
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 17 of 81  April 6, 2018  
 as the optimal dose of KP415  at the end of the Dose 
Optimization Phase, either 20, 30 or 40 mg KP415, or 
matching placebo.  Blinded study medications of each 
treatment will be administered from Sunday  (the day a fter 
Visit 5)  to Saturday  (Visit 6) . On Saturday  (Visit 6) , the 
blinded doses of study drug will be administered at the school 
site by [CONTACT_891171]. On the other days  of the Treatment Phase , the medication 
will be taken in the morning at home.  
All study drugs will be given orally with [ADDRESS_1247543] will complete 
abbreviated practice laboratory classroom sessions with 4 
SKAMP/PERMP assessments designed to mirror the p re-
dose to [ADDRESS_1247544] -dose period of the full -length laboratory 
classroom session of Visit 6 . The pre -dose assessment (after 
2 days of no drug) at Visit [ADDRESS_1247545] dose of KP415 or Placebo in the Double -Blind 
Treatment Phase . 
ADHD 
SEVERITY/EFFICACY 
EVALUATION CRITERIA  The following scales will be used during the Open-Label 
Dose Optimization Phase to globally assess the changes in 
ADHD severity from week to week:  
• ADHD -Rating Scale -5 (ADHD -RS-5) The ADHD -
RS-5 is an 18 -item scale based on Diagnostic and 
Statistical Manual of Mental Disorders, 5th edition 
(DSM -5) (American Psychiatric Association 2013) 
criteria of ADHD that rates symptoms on a 4 -point 
scale. Each item is scored u sing a combination of 
severity and frequency ratings from a range of 0 
(reflecting no symptoms or a frequency of never or 
rarely) to 3 (reflecting severe symptoms or a 
frequency of very often), so that the total ADHD -RS-
5 scores range from 0 to 54. The 18 items can be 
divided into two 9 -item subscales: One for 
hyperactivity/impulsivity and the other for 
inattentiveness. Scores will be obtained during a 
clinician -directed interview with the 
parent/ guardian/ caregiver  at each visit.  
• Clinical Global Impressions –Severity (CGI -S): The 
CGI-S is a clinician -rated scale that evaluates the 
severity of psychopathology (ADHD symptoms in 
the study) on a scale from 1 (not at all ill) to 7 
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 18 of 81  April 6, 2018  
 (among the most severely ill) (Busner and Targum 
2007).  
• Clinical Global Impressions –Improvement (CGI -I). 
The CGI -I is scored from 1 (very much improved) to 
7 (very much worse).  
The following scale will be used to assess the effect ofKP415 
during the Open -Label Dose Optimization Phase and the 
efficacy of KP415 versus placebo during the Double -Blind 
Treatment Phase:  
• Conners 3rd Edition -Parent (Conners 3 -P). The 
Conners 3 -P (short form) is a 43-item 
parent /guardian/ caregiver  report that provides 
evaluation of inattention, hyperactivity/impulsivity, 
learning problems, executive functioning,  aggression, 
and peer relationships. The parent/ guardian/ caregiver  
will assess changes in ADHD symptoms via the 
Conners 3 -P questionnaire at baseline (Visit 2, Day 0) 
and at each visit during the Dose -Optimization and the 
Treatment Phase . 
•  Weekly Rating of Evening and Morning Behavior - 
Revised (WREMB -R) Scale : The 11-item WREMB -R 
questionnaire is a parent -rated questionnaire that was 
developed to assess  behaviors for their severity during 
the morning hours (3 items) and evening hours  (8 
items) (Carlson 2007). The  possible score for each 
item ranges from 0 (no difficulty) to 3 (a lot of 
difficulty) . The Investigator or designee will obtain 
the scores for the  WREMB -R questionnaire by 
[CONTACT_301288]/guardian/caregiver at Visits 2, 
5 and 6. The assessment at Visit 2 is the baseline 
assessment (after washout of ADHD medications, if 
applicable); the assessments at Visits 5 and 6 are 
evaluations at the end of the Dose Optimization and 
Treatment Phase, respectively.  
The following scales wil l be used to assess the efficacy of 
KP415 versus placebo during the Double -Blind Treatment 
Phase:  
• Swanson, Kotkin, Agler, M -Flynn, and Pelham 
(SKAMP) Rating Scale  will be performed at Visit 4, 
Visit 5, and Visit 6.  
The SKAMP scale is a validated rating of classroom 
behaviors. It is comprised  of 13 items (grouped under 
the subcategories of attention, deportment, quality of 
work, and compliance) , on which subjects are rated 
according to a 7 -point scale (0 = normal to 6 = 
maximal impairment) by [CONTACT_402546] p ersonnel 
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 19 of 81  April 6, 2018  
 (Swanson 1999 ). The SKAMP -Combined (SKAMP -
C) score is obtained by [CONTACT_891172] 13 items. The SKAMP -Deportment 
(SKAMP -D) score is a measure of behavior and 
comprises of 4 items. The SKAMP -Attention 
(SKAMP -A) score is a measure of attention and 
comprises 4 items. Higher SKAMP scores signify 
greater impairment. The SKAMP -C score will be 
used in the primary efficacy endpoint.  
• Permanent Product Meas ure of Performance 
(PERMP) Rating Scale will be performed  at Visit 4, 
Visit 5  and Visit 6.  A Placement PERMP will be 
performed at Visit 2 (Day 0)  to assure that subjects 
can complete at least the basic level of math 
problems and to determine the appropriate level of 
math to be assigned during the practice laboratory 
classroom day  at Visit [ADDRESS_1247546] will be determined for use in 
the remainder of the study (Visits 5 and 6).  
The PERMP is an individually calibrated  five-page 
mathematics workshee t consisting of 400 problems. 
Subjects will be instructed by [CONTACT_891173] 10 minutes. Performance will be 
evaluated using two scores: The number of problems 
attempted (PERMP -A) and the numbe r of problems 
correct (PERMP -C). 
SAFETY EVALUATION 
CRITERIA  Adverse events, vital signs, physical examination, ECGs, 
clinical laboratory measurements , and C -SSRS scores  will be 
evaluated for s afety.  
DURATION OF SUBJECT 
PARTICIPATION AND 
DURATION OF STUDY  Subjects will participate in the study as outpatients for up to 
85 days, including  up to 49 days of Screening; a 21-day (±3 
days) Dose Optimization Phase, a 7 -day Treatment Phase,  
and a F ollow -Up Visit (3 ±[ADDRESS_1247547] dose of the Treatment Phase ). 
MEDICATION 
RESTRICTIONS  Subject ’s meeting all eligibility requirements will be 
prohibited/limited to receive certain medications in the trial:  
• Stimulant ADHD medications (with the exception of 
study drug), including herbal medications, are prohibited 
from 5 days prior to the start of the Dose Optimization 
Phase (Day 0) to the end of the Follow -Up Visit or Early 
Termination Visit. These include:  methylpheni date, 
amphetamine, Ritalin®, Ritalin® SR, Metadate® ER, 
Concerta®, dextromethylphenidate, Focalin®, 
dextroamphetamine, Dexedrine®, Adderall®. 
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 20 of 81  April 6, 2018  
 • Non-Stimulant ADHD medications are prohibited from 
21 days prior to the start of the Dose Optimization Phase 
(Day 0) to the end of the Follow -Up Visit or Early 
Termination Visit. These include:  Atomoxetine, 
guanfacine, clonidine; and SSRIs such as fluoxetine  and 
paroxetine . 
• The following medications are prohibited from 21 days 
prior to the start of the Dose Optimizati on Phase (Day 0) 
to the end of the Follow -Up Visit or Early Termination 
Visit:  
o Tricyclic antidepressants.  
o Monoamine oxidase inhibitors (MAOIs).  
o Mood stabilizers (e.g., lithium, valproate, 
quetiapi[INVESTIGATOR_050]).  
o Antipsychotics (e.g., risperidone, olanzapi[INVESTIGATOR_050]).  
o Coumari n anticoagulants.  
o Anticonvulsants.  
o Halogenated anesthetics.  
o Phenylbutazone  
o Coumari n anticoagulants  
 
• Sedative hypnotics/sleep enhancers  (with the exception of 
melatonin) are prohibited from 14 days prior to the start of 
the Dose Optimization Phase (Day 0) to the end of the 
Follow -Up Visit or Early Termination Visit.  
• Melatonin is allowed if subjects have taken it for more 
than 30 days befo re the start of the Dose Optimization 
Phase (Day 0) and are on a stable dose. Otherwise, 
melatonin is prohibited from 5 days prior to the start of the 
Day 0  to the end of the Follow -Up Visit or Early 
Termination Visit . 
Medications allowed during the course  of the study include 
nasal steroids, bronchodilators, acetaminophen and 
nonsteroidal anti -inflammatory medications ; non -sedating 
antihistamines such as cetirizine, loratadine, and 
fexofenadine; mometasone; and approved courses of 
prescription and nonprescription medications for the 
treatment of acute illnesses.   
EFFICACY ENDPOINTS  The primary efficacy evaluation is based on SKAMP and 
PERMP scores at pre-dose, and at 0.5. 1, 2, 4, 8, 10, 12, 
and [ADDRESS_1247548] -dose during the full laboratory classro om 
day at Visit 6 . The baseline SKAMP score is measured  at 
pre-dose at Visit 5 . 
Primary Efficacy Variable:  
• Average of the change from baseline (measured at 
Visit 5) of the  SKAMP -C score s collected across the 
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 21 of 81  April 6, 2018  
 laboratory classroom day at Visit 6.  
Secondary Efficacy Variables:  
• Change from baseline (measured at Visit 5) of the 
SKAMP -C score s measured at each time point on the 
laboratory classroom day  at Visit [ADDRESS_1247549] of 
KP415.  
• Change from baseline of the s cores measured at each 
time point and the average  of the scores collected 
across  the laboratory classroom day at Visit 6 , for the 
following endpoints : 
o SKAMP -D and SKAMP -A scores  
o PERMP scores  
o PERMP -A and PERMP -C scores  
• WREMB -R scores (total score , and morning and 
evening subscore ) at Baseline  (Visit 2) , Visit 5 and 
Visit 6.  
SAFETY ENDPOINTS  The occurrence of Treatment -Emergent Adverse Events 
(TEAEs) will be assessed starting following the first dose  of 
open -label drug (KP415), and ending with the Follow -Up 
Visit or Early Termination Visit. Additional safety 
evaluations will include physical examination s, vital signs, as 
well as height and weight, ECG parameters, clinical 
laboratory tests, and a follow -up C -SSRS administered at 
each study visit. AEs during the Open -Label Dose 
Optimization Phase and the Double -Blind Treatment Phase 
will be will be reported and analyzed separately.  
ANALYSIS 
POPULATIONS  Intent -to-Treat (ITT) Population:  All randomized subjects 
who receive at least one dose of double -blind study 
medication and have at least one SKAMP -C assessments  at 
Visit 6 . 
Per-Protocol (PP) Population:  ITT subjects who received 
the morning dose of double -blind study medicati on at the 
laboratory test session, who have all [ADDRESS_1247550]-dose SKAMP -C 
assessments  at Visit 6 , who did not miss more than 2 days of 
therapy during the Double -Blind Treatment Phase, and did 
not use prohibited medications during the Double -Blind 
Treatment Phase . 
Overall Safety Population:  All subjects who entered the 
Open -Label Dose Optimization phase and received at least 
one dose of open -label study medication and had at least 
one post -dose safety assessment . 
STATISTICAL 
ANALYSES – 
TREATMENT PHASE  Efficacy:  Primary and secondary efficacy analyses will be 
performed on the ITT and PP populations. Descriptive 
statistics for the all SKAMP and PERMP  scores  and subscale 
Protocol KP415.E01 Amendment #[ADDRESS_1247551] rage of the scores  collected 
across the laboratory classroom day . The difference between 
treatments (KP415 vs. placebo) will be evaluated  for each 
variable using repeated measures analyses . The treatment 
comparison will be conducted as a two -sided test at the 5% 
level of significance. Standard errors and 95% confidence 
intervals (CIs) will be c alculated.  
Onset of clinical effect is defined as the earliest post -dose 
time point at which the difference between KP415 and 
Placebo is statistically significant (p< 0.05). The duration of 
the treatment effect  is defined as the length of the time 
interval, such that statistical significance was reached at each 
time point of this interval . 
 
Subgroup analyses will include efficacy and safety endpoints 
by [CONTACT_3885], dose, age, and gender . 
Safety:  The frequencies of adverse events (AEs), the results 
of laboratory assessments, physical examinations, vital signs, 
ECGs, and suicidal ideation (assessed using the C -SSRS) will 
be summarized descriptively (by [CONTACT_3148] , if ap plicable)  in 
the Overall Safety Population . 
STUDY PROCEDURES  The study procedures are outlined in the Schedule of 
Events ( Section 1 ).  
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 23 of 81  April 6, 2018  
 1. SCHEDULE OF  EVENTS  
ASSESSMENTS  
SCREEING 
PHASE  
OPEN -LABEL  
DOSE OPTIMIZATION PHASE  27 
TREATMEN
T PHASE  
ET 29 
(EOS)  
FOLLOW -UP 
(EOS)  
Study Day   -49 to 
-1 0 1-6 
(±3 
Days)  7 
(±3 
Days)  8-13 
(±3 
Days)  14 
(±3 
Days)  15-20 
(±3 
Days)  21 
(±3 
Days)  22-27 
(±3 
Days)  28 28 
(±3 
Days)  - 29-33 
(±2 
Days)  
Visit Number  1 2  3  4  5  6 - 7 
Parental Permission /Written 
or Verbal Assent  X            
ADHD Diagnosis and 
Confirmation [ADDRESS_1247552] 3 X            
Inclusion/Exclusion  X X  X  X  X     
Demographics  X            
Medical History 4 X X  X  X  X    X 
Physical Examination 5 X          X X 
Body Weight, Height, BMI 6 X          X X 
Vital Signs 7 X X  X  X  X  X X X 
12-Lead ECG 8 X          X X  
Chemistry/ 
Hematology/Urinalysis  X          X X 
Urine Alcohol/Drugs of 
Abuse  Screen [ADDRESS_1247553] 11 X X      X   X X 
C-SSRS 12 X X  X  X  X  X X X 
Washout ADHD Med s 13 X            
Open -Label KP415  Dosing 
14   X X X X X X     
Randomization 15        X     
Double -Blind Study Drug 
Administration 16         X X   
Drug Accountability & 
Compliance Assessment     X  X  X  X   
Laboratory Classroom 
Sessions 17      X  X  X   
ADHD -RS-5 18  X  X  X  X     
CGI-S 19 X X  X  X  X     
CGI-I 20  X  X  X  X     
Conners  3-P 21  X  X  X  X  X   
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 24 of 81  April 6, 2018  
 ASSESSMENTS  
SCREEING 
PHASE  
OPEN -LABEL  
DOSE OPTIMIZATION PHASE  27 
TREATMEN
T PHASE  
ET 29 
(EOS)  
FOLLOW -UP 
(EOS)  
Study Day   -49 to 
-1 0 1-6 
(±3 
Days)  7 
(±3 
Days)  8-13 
(±3 
Days)  14 
(±3 
Days)  15-20 
(±3 
Days)  21 
(±3 
Days)  22-27 
(±3 
Days)  28 28 
(±3 
Days)  - 29-33 
(±2 
Days)  
Visit Number  1 2  3  4  5  6 - 7 
WREMB -R Questionnaire 22  X      X  X   
2-day washout of open -label 
KP415 23       X      
SKAMP  and PERMP  24      X  X  X   
Adverse Events 25   X X X X X X X X X X 
Concomitant Medications 26 X X  X  X  X  X X X 
EOS = End of Study; ET = Early Termination; BMI = Body Mass Index; ECG = Electrocardiogram; 
MPH = methylphenidate; see footnotes for  other abbreviations.  
 
1. ADHD Diagnos is based on the  Statistical Manual of Mental Disorders - Fifth Edition (DSM -5) 
criteria for a primary diagnosis of ADHD (combined, inattentive, or hyperactive/impulsive 
presentation) and confirmed by [CONTACT_891174] (MINI -KID) . 
2. A Placement Permanent Product Measure of Performance (PERMP)  will be performed at Visit 2 
(Day 0)  to assure that subjects can complete at least the basic level of math proble ms and  to 
determine the appropriate level of math to be assigned during the practice laboratory classroom day  at 
Visit [ADDRESS_1247554]: Subjects will take a size [ADDRESS_1247555] be able to easily swallow the size 3 
capsule to be eligible for further study participat ion. 
4. Medical History: A complete medical history including chronic conditions, relevant surgical 
procedures (with start date), history of alcohol and recreational drug use . 
5. Complete physical examination at Screening, and at ET (if possible)  or Follow -Up. 
6. All ph ysical examinations will include the measurement of body weight. Height and BMI at 
Screening only.  
7. Vital sign measurements will be obtained after the subject has been seated for at least 3 minutes. Vital 
signs will include sitting blood pressure (systolic and diastolic measurements), pulse rate (beats per 
minute), respi[INVESTIGATOR_697] (breaths per minute), and oral temperature. Vital signs will be collected once 
at each visit. On the full laboratory classroom day (Day 28 ±3 days, Visit 6), vital signs will be 
collected at any time before dosing.  
8. Electrocardiogram (ECG): A [ADDRESS_1247556] 3 minutes. Abnormal ECGs may be repeated for confirmation in which case only 
the repeated ECG will be  recorded. The QT interval corrected for heart rate will be calculated with 
Fridericia ’s formula (QTc F). ECGs  will be obtained at Screening , and at Early Termination or 
Follow -Up. 
9. Urine Screen for Alcohol  and Drugs of Abuse: Urine samples will be tested fo r alcohol, and drugs of 
abuse (amphetamines, methamphetamines, benzodiazepi[INVESTIGATOR_1651], barbiturates, cannabinoids, cocaine, 
opi[INVESTIGATOR_355752]) at Screening (Visit 1). If the urine test is positive for any of the analytes 
at Screening, the subject will b e excluded from study participation, with the exception of the 
following: Depending on a subject's current ADHD medication at Screening, the urine screen at 
Protocol KP415.E01 Amendment #[ADDRESS_1247557] be washed out by [CONTACT_2006] 0.  
10. Urine Screen for Methylphenidate (MPH): Urine samples will be tested for MPH  at Screening (Visit 
1), at Visit 2 , and before administration of study drug at Visit 5.  A urine dipstick (e.g., NarcoCheck®) 
will be used to screen for the presence of MPH  in the urine . If a subject's current ADHD medication 
at Screening  contains MPH , the urine screen at Screening may test positive for MPH . Since all 
ADHD  medications must be washed out by [CONTACT_2006] 0, they must test  negative on Day 0 (Visit 2) for 
subjects to be eligible to continue in the study . 
11. Pregnancy Test: performed for female subjects of childbearing potential . A serum β -hCG pregnancy 
test will be performed at Screening. A urine pregnancy test will be performe d at Visit 2, Visit [ADDRESS_1247558] from further participation in the study.  
12. Columbia Suicide Severity Rating Scale (C -SSRS): The “Children’s Baseline/Screening” version will 
be assessed at Screening, and the “Children’s Since Last Visit” version will be assessed at all visits of 
the Dose  Optimization Phase (Visits 2, 3, 4 and 5), at Visit 6, and at Follow -Up or Early Termination.  
Subjects who have any history of attempted suicide or clinically significant suicidal ideation based on 
the C -SSRS assessment, in the opi[INVESTIGATOR_689] , at any time before the last dose of study 
drug, will be exclude d from further participation i n the study.  
13. Subjects must wash out ADHD medications prior to Day 0  (Visit 2) . Stimulant ADHD medications 
(with the exception of study drug), including herbal medications, are prohibited from 5 days prior to 
the start of the Dose Optimization Phase (Day 0)  to the end of the Follow -Up Visit or Early 
Termination Visit.  Before or on the day during the screening period that subjects will need to start the 
washout of their ADHD medications ( for example, 5 days before Visit 2  for stimulants ), study site 
staff wil l contact [CONTACT_423]’s parent/guardian by [CONTACT_355766] (“washout 
phone call”).  Non-Stimulant ADHD medications are prohibited from 21 days prior to the start of the 
Dose Optimization Phase (Day 0) to the end of the Follow -Up Visit or  Early Termination Visit. Other 
prohibited medications with their associated time windows when they are prohibited are listed in 
Section 12.1  of the protocol.  
14. KP415  Dose Optimization: Subjects will begin taking open -label KP415 at home the morning 
followin g Visit 2. The starting dose of KP415 (Days 1 -7 ±3 days) will be 30 mg/day. KP415 dose 
adjustments, if needed, will be performed at approximately weekly intervals between visits (at Visits 
3 and 4). Actual visit dates may deviate from exactly being spaced 7 days apart such that the total 
duration of the Dose Optimization Phase is 3 weeks (21 ±3 days ). The daily doses of KP415 used in 
the Dose Optimization Phase will be 20, 30 and 40 mg (dose optimization range of ≥20 and ≤40 mg). 
At Visits 3 and 4, based on  the CGI sc ores, interview with the parent/ guardian/ caregiver , and safety 
data, the Investigator will evaluate the subject’s therapeutic responses and tolerability to treatment 
and decide whether the current KP415 dose should be increased, decreased, or re main the same for 
the next week of dosing. If subjects experience symptoms of intolerance during the at -home 
treatment, they must contact [CONTACT_977], and, at the discretion of the Investigator, their KP415 
dose may be adjusted before the next schedu led visit. Unscheduled visits between Visits 2, 3, 4, and 5 
are allowed as needed, at the discretion of the Investigator.  
At Visit 5, the Investigator will evaluate the eligibility criter ia for continuation into the subsequent 
Double -Blind Treatment Phase.  For subjects eligible for the Treatment Phase, the optimal daily 
KP415 dose will be used as the daily KP415 dose (or matching placebo) in the Treatment Phase.  
15. Randomization: Subjects able to tolerate at least 20 mg/day of KP415  during the Dose  Optimizatio n 
Phase  and with an adequate dose -response  will be randomized on a 1:1 basis to a treatment of KP415 
(Treatment A) or placebo (Treatment B). The appropriate  blinded study drug to be taken at home 
once-a-day in the morning on each of the following 6 days (D ays 2 2-27 ±3 days ) will be dispensed to 
the subjects.  
16. Study Drug Administration ( Double -Blind Treatment Phase): Subjects on an optimized KP415  dose 
of 20, 30, and 40 mg at the end of the Dose  Optimization Phase will receive 20, 30, and 40 mg, 
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 26 of 81  April 6, 2018  
 respectively, of KP415 capsules or matching placebo capsules once -per-day for 7 days in the 
morning. No adjustment of the dose of study drug will be permitted. All study drugs will be given 
orally. On Days 22-27 ±3 days , subjects will take study drug at ho me under supervision of their 
parent or legal guardian. The final dose of study drug will be administered on the 7th day of the 
Double -Blind Treatment Phase (Day 28 ±3 days ; Visit 6) at the laboratory school by [CONTACT_464]. The 
capsule with study drug will  be swallowed with approximately 240 mL of water. Additional water 
may be given if needed, and the volume of additional water will be recorded.  
17. Laboratory Classroom Days:  At Visit [ADDRESS_1247559] will complete abbreviated practice 
laboratory classroom session s with 4 SKAMP/PERMP assessments  designed to mirror the p re-dose to 
2-hour post -dose period of the f ull-length laboratory classroom session  of Visit [ADDRESS_1247560] dose of KP415 or Placebo in the 
Double -Blind Treatment Phase . 
18. ADHD -Rating Scale -5 (ADHD -RS-5) assessment: 1 assessment at the indicated visits.   
19. Clinical Global Impressions –Severity (CGI -S) scale assessment: 1 assessment at the indicated visits.  
20. Clinical Global Impressions –Improvement (CGI -I) scale assessment: 1 assessment at the indicated 
visits.  CGI-I score  of 1 or 2 points (“Very Much Improved”  or “Much Improved” ) at the end of the 
Open -Label Dose Optimization Phase.  
21. Conners 3rd Edition -Parent (Conners 3 -P): The parent/ guardian/ caregiver will assess changes in 
ADHD symptoms via the Conners 3 -P questionnaire at baseline (Visit 2) and at each visit during the 
Dose -Optimization Phase and the Treatment Phase . 
22. Weekly Rating of Evening and Morning Behavior - Revised (WREMB -R) Scale: The Investigator or 
designee will obtain the scores for the WREMB -R questionnaire by [CONTACT_557154]/guardian/car egiver at Visits 2, 5 and 6.   
23. Washout of open -label KP415 for 2 days before Visit 5: No study drug will be administered durin g 
the 2 days before the baseline SKAMP and PERMP assessment at p re-dose of Visit 5 . The 2 days of 
NO drug (2 skipped doses) entail the doses on the day before Visit 5 and the day before that.  
24. Swanson, Kotkin, Agler, M -Flynn, and Pelham (SKAMP) and Permanent Product Measure of 
Performance (PERMP)  score assessment s:  
• Visit 4 (Day 14 ±3 days): A bbreviated practice laboratory classroom se ssion  with 
SKAMP/PERMP  assessments at pre -dose and at 0.5, 1, and [ADDRESS_1247561] will be determined for use in the remainder of the study 
(Visits 5 and 6).  
• Visit 5 (Day 21 ±3 days): A bbreviated pr actice laboratory classroom session  with 
SKAMP/PERMP  assessments at pre -dose and at 0.5, 1, and [ADDRESS_1247562] -dose. The pre -dose 
assessment (after 2 days of no drug) will be recorded as the baseline for the SKAMP and 
PERMP.  
• Visit 6 (Day 28 ±3 days ): Full laboratory classroom day with SKAMP/PERMP assessments at 
pre-dose and at 0.5, 1, 2, 4, 8, 10, [ADDRESS_1247563] -dose. 
At Visits 4, 5, and 6, subjects will be administered unblinded  study drug at the study site.  
25. Adverse Events: To be assessed and recorde d in the eCRF following the first dose of open -label drug 
(KP415) , on Day [ADDRESS_1247564]’s parent/guardian will be 
instructed to contact [CONTACT_355777].  
26. Concomitant Medications: new and/or changed medications and dose, medical treatments and/or 
therapi[INVESTIGATOR_728272] -Up or Early Termination.  
27. Actual visit dates in the Dose Optimization Phase may deviate from exactly be ing spaced 7 days apart 
such that the total duration of the Dose Optimization Phase ranges between 18 and 24 days ( 21 ±3 
days). 
28. The end of the Treatment Phase is on Day 28  ±3 days  (Visit 6), after all post -dosing procedures 
including all laboratory classro om assessments are completed.  
29. At the discretion of the Investigator, ensuring the safety of the subjects, any ET procedures that were 
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 27 of 81  April 6, 2018  
 already performed on the same day as part of the procedures of the Dose  Optimization or Treatment 
Phase, do not need to be  repeated . 
2. STUDY DESIGN SCHEMATIC  
 
Note: The study days listed for Visits 3, 4, and 5 may deviate with ±3 days for individual subjects such that 
the total duration of the Dose Optimization Phase is 21 days ±3 days  (duration ranging from  18 to 24 days) . 
Any deviation of the targeted 21 -day Dose Optimization Phase will be carried  over into the actual days for 
the subsequent visi ts: Visit  6 at Day 28 ±3 days , and Visit 7 at days ranging from Day 29 ±3 days  to Day 33 
±3 days . 
  

Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 28 of 81  April 6, 2018  
 3. BACKGROUND  
3.1. Attention -Deficit Hyperactivity Disorder (ADHD)  
ADHD  is a common neurobehavioral disorder that occurs in 6 -8% of children and 4 -5% of adults 
worldwide (Wilens et al. 2008). The [ADDRESS_1247565] common and effective therapeutics for the treatment of ADHD are 
CNS stimulants , which  contain amphetamine or methylphenidate  (MPH) . Amphetamine -containing 
products include brand names such as Adderall®, Dexedrine®, Dextrostat®, and  Vyvanse®. 
Methylphenidate containing products include Metadate®, Concerta®, Daytrana®, Ritalin®, 
Methylin®, Quilivant®, and Focalin®. Positive effects on behavior and academic productivity are 
well established for stimulant medications such as MPH  (Wilens  and Biederman 1992) . Several 
studies have shown that, in children with ADHD, MPH improves cl assroom functioning, notably 
by [CONTACT_728292], accuracy and 
improvement in teacher ratings. In addition, MPH has been shown  to improve performance in 
children for several  cognitive tasks, incl uding measures of attention and memory . 
3.2. Laboratory Classroom Studies  
Methylphenidate has been an important treatment option for ADHD for many years, including for 
the treatm ent of children with ADHD. Patients with ADHD are titrated to their optimal dose of 
methylphenidate based on assessments of efficacy and tolerability.  Clinical studies with school -age 
children with ADHD in a laboratory classroom setting  (Lawrence et al. 20 04; Swanson et al. 2004) 
are ideally suited for the assessment of stimulant medications and has been previously employed in 
studies of methylphenidate (Swanson et al. 2003, 2004) and amphetamine medications (McCracken 
et al. 2003; Swanson et al. 1998). Analog classroom studies facilitate repeated observational 
measures of attention, deportment, and cognitive performance, and assessment of time course 
effects in a cont rolled setting (Swanson et al.  2003; Lawrence et al. 2004 ). The model enables 
investigators to collect with carefully controlled methods , documented assessments of drug effect 
by [CONTACT_891175].  
4. KP415: A PROD RUG CONJUGATE  
KemPharm is develop ing KP415 as an extende d release  (ER)  prodrug of d -threo -MPH HCl. 
Chemically, KP415 consists of a single d -threo -MPH molecule covalently attached via a carbamate 
bond to a methylene oxide linker which in turn is connected to the nitrogen of the pyridine ring of 
a nicotinoyl -serine moiety. The covalent linkage makes KP415 a new chemical entity (NCE). 
Results from preliminary in vivo studies in rats have shown that the prodrug has unique 
pharmacokinetic (PK) properties that suggest it will have reduced intranasal and intravenous ab use 
potential.  
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 29 of 81  April 6, 2018  
 As a prodrug, KP415 represents a potential abuse -deterrent form of MPH with abuse -deterrent 
properties that are imparted at the molecular level. Some of the KP415 attributes that make it worthy 
of further development are highlighted below:  
• KP415 has negligible pharmacological activity at key receptors that are responsible for the 
efficacy of d -MPH for the treatment of ADHD.  
• When administered intranasally or intravenously  in rats , KP415  resulted in  d-MPH  plasma 
concentrations that are significantly reduced when compared to  d-MPH HCl . 
• KP415  exhibits chemical stability when subjected to certain hydrolytic conditions with the 
intention to extract methylphenidate . 
5. OVERVIEW OF CLINICAL STUDIES  WITH KP415  
The p harmacology, metabolism and toxicology of methylphenidate are well established (Challman 
2000, Leonard 2004). Methylphenidate is a CNS stimulant approved for the treatment of ADHD 
and narcolepsy. Methylphenidate inhibits the reuptake of dopamine and norepi [INVESTIGATOR_238], increased 
dopaminergic and noradrenergic activity in the prefrontal cortex may explain its efficacy in ADHD.  
Common side effects of methylphenidate include nervousness, agitation, anxiety, sleep problems 
(insomnia), stomach pain, decreased appeti te, weight loss, nausea, vomiting, dizziness, palpi[INVESTIGATOR_814], 
headache, vision problems, increased heart rate, increased blood pressure, sweating, skin rash, 
psychosis, and numbness, tingling, or cold feeling in hands or feet.  When abused, methylphenidate 
produces toxicity similar to other CNS stimulant overdoses  (Morton 2000). Supra -therapeutic doses 
have shown to cause delirium, hallucination s, bruxism (jaw -grinding), and trismus (jaw clenching)  
(Morton 2000).  
5.1. Study KP415.101  
This Phase 1 proof -of-concept t rial (Study KP415.101) was designed to assess the PK of 32 mg of 
KP415 API (liquid, dissolved in water) compared with 36 mg of Concerta® (tablet) after oral 
administration under fasted conditions. Twenty -four (24) healthy adult volunteers were enrolled in 
this open -label, single -dose, two -treatment, two -period PK trial. Dosing levels in each treatment 
were not molar equivalent amounts of d -MPH: 36 mg Concerta® contained approximately 12% 
more d -MPH than 32 mg of the KP415 prodrug API (standalone KP415).  
KP415 API [INVESTIGATOR_728275] d -MPH into the bloodstream which is consistent 
with previously collected preclinical data. After KP415 API [INVESTIGATOR_728276], the mean peak 
concentration (C max) of d -MPH was 2.9 ng/mL at a median T max of 8 hr com pared to 8.0 ng/mL at 
6 hr after Concerta®. 
The mean systemic exposure (AUC 0-last) for d -MPH was 44 ng•hr/mL after KP415 API [INVESTIGATOR_891159]415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 30 of 81  April 6, 2018  
 versus 97 ng•hr/mL after Concerta® dosing. The mean total systemic exposure (AUC 0-inf) for d -
MPH was 100 ng•hr/mL after KP4 15 API [INVESTIGATOR_728278] 102 ng•hr/mL after Concerta® dosing. 
The mean terminal elimination plasma half -life (T 1/2) of d -MPH was 25 hr after KP415 API [INVESTIGATOR_728277] 4 hr after Concerta®. 
After oral dosing of standalone KP415, it appears that that there is ra pid absorption of prodrug 
followed by [CONTACT_728293] d -MPH resulting in a gradual onset followed by a slow extended release 
of d-MPH. The later T max and longer T 1/2 for d -MPH after KP415 dosing indicate that KP415 as a 
prodrug of d -MPH has extended -releas e (ER) properties that support a once -per-day dosing 
schedule for an ADHD indication. The ER properties inherent in the KP415 prodrug molecule can 
subsequently provide sustained d -MPH exposure, as desired for a once -per-day treatment of ADHD 
in adults. Sin ce plasma concentrations of the inactive intact KP415 molecule were measured after 
oral KP415 dosing, circulating levels of prodrug may contribute to the ER profile of KP415 -derived 
d-MPH. No l -MPH levels were detected after KP415 dosing and very low l -MPH  levels were 
measured after Concerta® dosing.  
Both treatments were generally well -tolerated. There were no apparent changes in vital signs and 
ECG parameters between treatments. Safety laboratory values were approximately the same after 
the treatment phase  versus those measured at Screening.  
5.2. Study KP415.109  
This Phase 1 open -label PK study included a treatment group wherein healthy adult volunteers were 
dosed with oral daily doses of 12 mg d -MPH API (immediate release comp onent ) and [ADDRESS_1247566] dose that will be 
used in the current protocol.  
The mean d -MPH plasma concentrations on Day 7  of Study KP415.109 are presented in Figure 1. 
The mean d -MPH trough concentration (C min; pre-dose on Day 7) was 3.3 ng/mL and the mean d -
MPH peak concentration (C max on Day 7 ) was 20 .9 ng/mL at a median T max of 1.5 hr. The mean 
systemic exposure over the dosing interval (AUC 0-24hr) for d -MPH was 208 ng•hr/mL and the mean 
terminal elimination plasma half -life (T 1/2) of d -MPH was 8.9 hr. The mean accumulation ratios 
(Day 7/Day 1 ratios) for C min, C max and AUC 0-24hr were 1.3 1, 1.20 and 1.3 4, respectively. The 
combination of 70%/30% KP415/d -MPH resulted in early peak d -MPH exposure followed by 
[CONTACT_12814] d -MPH exposure, as desired for chronic, once -per-day treatment of  ADHD in a pediatric 
population . The efficacy and safe ty of this combination in children 6 -12 years old with ADHD will 
be studied in the study presented in this protocol.  
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 31 of 81  April 6, 2018  
 Figure 1: Mean (N=10) d -Methylphenidate (d -MPH) Concentrations after the 7th Oral Daily 
Dose of 12 mg d -MPH and 56 mg KP415 Prodrug (Togeth er Equivalent to 40 mg d -MPH)  
 
6. STUDY RATIONALE  
The current study will investigate the effica cy of KP415 compared to placebo and determine the 
onset and duration of the clinical effect of KP415 in treating children 6 -12 years old with ADHD . 
7. STUDY OBJECTIVES  
7.1. Primary Objective  
To determine the efficacy of KP415 compared to placebo in treating c hildren 6 -12 years old with 
ADHD  in a laboratory classroom setting.  
7.2. Secondary Objective s 
• To determine the onset and duration of the clinical effect of KP415 in treating ADHD in 
children 6 -12 years old in a laboratory classroom setting.  
• To determine the safety and tolerability of KP415 compared to placebo in treating children 
6-12 years old wi th ADHD in a laboratory classroom setting.  

Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 32 of 81  April 6, 2018  
 8. INVESTIGATIONAL PLAN  
8.1. Study Design  
The study is a multicenter, dose -optimized, double -blind, randomized, placebo -controlled, parallel 
efficacy laboratory classroom study with KP415 in children with Attention -Defici t/Hyperactivity 
Disorder (ADHD). The study will consist of a Screening Period, an Open -Label Dose Optimization 
Phase, a Double -Blind Treatment Phase and a Follow -Up Visit, as follows : 
• Screening Period:  Subjects will undergo a screening period up to 49 days prior to 
entering into the Open -Label Dose Optimization Phase . 
• Open -Label Dose Optimization Phase: During the Dose Optimization phase, subjects 
will be titrated to doses of 20, [ADDRESS_1247567] 
individual dose -response in the opi[INVESTIGATOR_689] . 
• Double -Blind Treatment Phase: Eligible subjects will be randomized to receive single 
daily doses of KP415 or Placebo for [ADDRESS_1247568] dose 
of the Treatment Period . 
• Follow -Up Visit:  3 ±[ADDRESS_1247569] dose of the Treatment Phase, 
subjects will enter a Follow -Up Visit to evaluate safe ty parameters  
8.2. Study Duration  
Subjects will participate in the study as outpatients for up to 85 days, including  up to 49  days of 
Screening; a 21 -day (±3 days) Dose Optimization Phase, a 7 -day Treatment Phase, and a Follow -
Up Visit (3 ±[ADDRESS_1247570] dose of the Treatment Phase ). 
9. SUBJECT SELECTION  
9.1. Number of Subjects  
An appropriate number of subjects will enter the Screening Period to enroll approximately 176 
subjects in the Open -Label Dose Optimization Phase, and to randomize approximately 140 subjects 
in the Double -Blind Treatment Phase, with the intention to complete with approximately 126 
subjects . Subjects who terminate early in the Treatment Phase will no t be replaced . 
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 33 of 81  April 6, 2018  
 9.2. Study Population  
Children 6 -12 years old with Attention -Deficit/Hyperactivity Disorder  who meet the 
inclusion/exclusion criteria listed below.  
9.2.1.  Inclusion Criteria  (at Screening , except when noted otherwise ) 
A subject will be eligible for incl usion in the study if all the following criteria apply:  
1. Subject must be at least 6 years old and less than 13 years old at the start of the Dose 
Optimization Phase (Day 0).  
2. Subject must have a b ody weight of at least [ADDRESS_1247571] dose of study drug has been taken. Childbearing potential is defined 
as fo llows: Girls under the age of [ADDRESS_1247572] period will be 
considered “not of child -bearing potential”. Girls of 12 years and older (including girls 
who will become 12 years or older during the study) will be considered “of child -bearing 
potential”, even if they have not yet had their first period. Irrespective of age, girls who 
have had their first period, will be considered “of child -bearing potential”.  
4. Subject must be in general good health defined as the absence of any clinically relev ant 
abnormalities as determined by [CONTACT_728295], vital signs, ECGs, medical history, and clinical laboratory values 
(hematology, chemistry, and urinalysis) at Screening. If any of the hematology, 
chemistr y, or urinalysis results are not within the laboratory's reference range, then the 
subject can be included only if the Investigator determines the deviations to be not 
clinically relevant.  
5. At least one parent/legal guardian of the subject must voluntary gi ve written permission 
for him/her to participate in the study.  
6. Subject must give  written  or verbal assent prior to study participation.  For verbal assent, 
the procedure will be documented and signed by a witness. A parent or guardian may 
not be the witness  for a child's verbal assent document.  
Protocol KP415.E01 Amendment #[ADDRESS_1247573] meet Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition 
(DSM -5) criteria for a primary diagnosis of ADHD (combined, inattentive, or 
hyperactive/impulsive presentation) per clinical eval uation and confirmed by [CONTACT_445596] (MINI -KID).  
8. Subject must have a score of at least 3 (mildly ill) on the clinician -administered Clinical 
Global Impressions –Severity (CGI -S) scale.  For su bjects requiring washout of ADHD 
medications, this criterion refers to a score following washout  (see Section 12.1 ). 
9. Subject must be able and willing to wash out current stimulant ADHD medications, 
including herbal medications from 5 days prior to the star t of the Dose Optimization 
Phase (Day 0), and abstain from taking these to the end of the Follow -Up Visit or Early 
Termination; and wash out non -stimulant ADHD medications from 21 days prior to the 
start of the Dose Optimization Phase (Day 0), and abstain from taking these to the end 
of the Follow -Up Visit or Early  Termination . 
10. An ADHD -Rating Scale -5 (ADHD -RS-5) total score (DuPaul et al. 2016) of at least 28 
at Visit 2 (Day 0). For subjects requiring washout of ADHD medications, this criterion 
refers to a score following washout (see Section 12.1 ). 
11. Subjects need to be able to perform at least the basic level of problems on the PERMP, 
based on a calibration assessment (Placement PERMP) performed at Visit 2 (Day 0).  
Based on the Placement PERMP, the level of math will be determined to be assigned 
during the practice laboratory classroom day at Visit 4.  
12. Subject, subject’s parent/legal guardian and caregiver (if applicable) must understand 
and be willing and able to comply with all study procedures and visit sch edule. If the 
subject is cared for by a caregiver for relevant parts of a school day, and if in this case, 
in the opi[INVESTIGATOR_689], the caregiver of the subject is more suitable for certain 
assessments (for example, Con ners 3-P and WREMB -R), the  caregiver will need to 
agree to the applicable procedures and visits . 
13. Subject , parent/ legal guardian  and caregiver (if applicable)  must be able to speak and 
understand English, and be able to communicate satisfactorily with the Investigator and 
study coor dinator.  
14. Subject must be able to swallow size 3 capsules as demonstrated by [CONTACT_891168] 
a size 3 capsule at Screening . 
9.2.2.  Exclusion Criteria  (at Screening , except when noted otherwise ) 
A subject who meets any of the following exclusion criteria will not  be enrolled into the study:  
Protocol KP415.E01 Amendment #[ADDRESS_1247574] from further participation in the 
study.  “Of childbearing potential” is defined in Section [ADDRESS_1247575] with any clinically significant chronic medical condition that, in the judgment 
of the Investigator, may interfere with the participant's abi lity to participate in the study.  
3. Subject has any diagnosis of bipolar I or II disorder, major depressive disorder, conduct 
disorder, obsessive -compulsive disorder, any history of psychosis, autism spectrum 
disorder, disruptive mood dysregulation disorder (DMDD), intellectual disability, 
Tourette's Syndrome, confirmed genetic disorder with cognitive and/or behavioral 
disturbances. Subjects with oppositional defiant disorder (ODD) are permitted to enroll 
in the study as long as ODD is not the primary focus o f treatment , and, in the opi[INVESTIGATOR_15960], the ODD is mild to moderate, and eligible subjects with ODD are 
appropriate and cooperative during Screening.  
4. Subject has generalized anxiety disorder or panic disorder that has been the primary 
focus o f treatment at any time during the [ADDRESS_1247576] has evidence of any chronic disease of the central nervous system (CNS) such 
as tumors, inflammati on, seizure disorder, vascular disorder, potential CNS related 
disorders that might occur in childhood (e.g., Duchenne Muscular dystrophy, 
myasthenia gravis, or other neurologic or serious neuromuscular disorders), or history 
of persistent neurological sym ptoms attributable to serious head injury. Past history of 
febrile seizure, drug -induced seizure, or alcohol withdrawal seizure is allowed . Subject 
taking anticonvulsants for seizure control currently or within the past [ADDRESS_1247577] has a c urrent (last month) psychiatric diagnosis other than specific phobia, motor 
skills disorders, oppositional defiant disorder, sleep disorders, elimination disorders, 
adjustment disorders, learning disorders, or communication disorders. Participants with 
school phobia or separation anxiety will not be eligible.  Subjects allowed to enroll with 
any of these DSM disorders will require written justification from the Investigator 
documenting why the conditions will not  interfere with participation and to emphasize 
that ADHD is the primary indication.  
7. Subject has any history of attempted suicide or clinically significant suicidal ideation  
based on the C -SSRS assessment, in the opi[INVESTIGATOR_689], at Screening or  at 
any time before the last dose of study drug.  
Protocol KP415.E01 Amendment #[ADDRESS_1247578] has any clinically significant unstable medical abnormality, chronic disease, or 
a history of a clinically significant abnormality of the cardiovascular (including 
cardiomyopathy, serious arrhythmias , structural cardiac disorders, or severe 
hypertension), gastrointestinal, respi[INVESTIGATOR_696], hepatic, or renal systems, or a disorder or 
history of a condition (e.g., malabsorption, gastrointestinal surgery) that may interfere 
with drug absorption, distribution , metabolism, or excretion of study drug. Active 
medical conditions that are minor or well -controlled are not exclusionary if they do not 
affect risk to the subject or the study results. In cases in which the impact of the condition 
upon risk to the subjec t or study results is unclear, the medical monitor should be 
consulted. Any subject with a known cardiovascular disease or condition (even if 
controlled) must be discussed with the medical monitor during Screening.  
9. Subject has a history or presence of abno rmal ECGs, which in the Investigator's opi[INVESTIGATOR_891160]. Screening site ECGs will be centrally over -read, and eligibility 
will be determined by [CONTACT_891176] -read report.  
10. Subject has a history of, or cur rently has a malignancy, except for non -melanomatous 
skin cancer.  
11. Subject has uncontrolled thyroid disorder as evidenced by [CONTACT_21923] 
(TSH) ≤0.8 x the lower limit of normal (LLN) or ≥1.25 x the upper limit of normal 
(ULN) for the referenc e laboratory at Screening.  
12. Subjects  with a history of substance abuse or treatment (including alcohol) within [ADDRESS_1247579] has a positive urine methylphenidate screen at the start of the Dose Optimization 
Phase (Day 0 , Visit 2 ). 
15. Subject who has initiated Cognitive Behavioral Therapy (CBT) for  the treatment of 
ADHD less than 1 month prior to Screening  (subjects on stable CBT will be allowed), 
has initiated behavioral therapy (including school based interventions)  less than 1 month 
prior to Screening , or is receiving behavioral therapy and in th e opi[INVESTIGATOR_891161] a stable routine for the duration of the study. 
Unavoidable changes in school -based interventions that occur during study participation 
Protocol KP415.E01 Amendment #[ADDRESS_1247580] has participated in a classroom study within 6 months prior to the start of 
Screening, or has participated in any other clinical study with an investigational 
drug/product within [ADDRESS_1247581] , parent/legal guardian and caregiver (if applicable at the Investigator’s 
discretion) has commitments during the study that would interfere with attending study 
visits.  
25. Subject or subject's family anticipates a move outside the geographic range of the 
investigative site during the study period, or plans extended travel inconsistent with the 
recommended visit interval during study duration.  
26. Subject's parent/legal guardian is a n investigational site staff member or a relative of an 
investigational site staff member  or a relative of an investigational site staff member . 
27. Subjects with a family member  living in the same household participating in another  
ADHD clinical trial during the period of Screening through the Follow -Up Visit will be 
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 38 of 81  April 6, 2018  
 excluded. Subjects with a family member living in the same household participating in 
the current clinical trial during the administration of study drug (Visits 2 to 6)  will be 
excluded. Different  subjects from the same family are allowed in this trial if they are in 
different cohorts , and there is no overlap  in time  from Visit [ADDRESS_1247582] to participate 
in this stu dy. 
9.2.3.  Eligibility Criteria (End of Dose Optimization Phase)  
Subjects will need to meet the following additional eligibility criteria at the end of the Dose 
Optimization Phase in order to enter into the Double -Blind Treatment Phase:  
1. A reduction of ≥30% reduction of ADHD -RS-5 from baseline (Day 0) during the Open-
Label Dose Optimization Phase.  
2. A CGI -I score of 1 or 2 points (“Very Much Improved” or “Much Improved”) at the end 
of the Open -Label Dose Optimization Phase.  
3. Acceptable tolerability of the optimized KP415  dose experienced during the Dose 
Optimization Phase.  
These assessments will be made based on the days before Visit 5 while still taking study drug (and 
NOT based on the 2 days of no study drug before Visit 5)  
9.2.4.  Rescreening  
Subjects who are screened outside the screening window may be rescreened for participation in a 
later cohort. Subjects who received any dose of study drug and are terminated early or are not 
eligible to continue in the Treatment Phase, are not eligible to participate in another cohort of the 
study  (and will not be rescreened) . 
10. STUDY TREATMENTS  
10.1. KP415  Dose Optimization  
In the Open -Label Dose Optimization Phase, daily treatments of 20, 30 and 40 mg open -label 
KP415 capsules will be administered (on e capsule/day), for the titration to an optimal daily KP415 
dose based on tolerability and best individual dose -response in the opi[INVESTIGATOR_689] . At 
Visits [ADDRESS_1247583] dose of unblinded  study drug.  
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 39 of 81  April 6, 2018  
 Subjects will begin taking open -label KP415  at home the morning following Visit 2. The starting 
dose of KP415 (Days 1 -7 ±3 days ) will be 30 mg/day. KP415  dose adjustments, if needed, will be 
performed at approximately weekly intervals  between visits (at Visits 3  and 4). Actual visit dates 
may deviate from exactly being spaced 7 days apart such that the total duration of the Dose 
Optimization Phase ranges betw een 18 and 24 days (21 ±3 days) . The daily doses  of KP415  used 
in the Dose Optimization Phase will be 20, 30 and 40 mg (dose o ptimization range of ≥ 20 and ≤ 40 
mg). At Visit s 3 and 4, based on the CGI  scores , interview with the parent /guardian/ caregiver , and 
safety data, the I nvestigator will evaluate th e subject’s therapeutic responses  and tolerability to 
treatment and decide whether the current KP415  dose should be increased, decreased, or remain the 
same for the next week of dosing . If subjects  experience symptoms of intolerance during the at -
home trea tment, they must contact [CONTACT_977], and, at the discretion of the Investigator, their 
KP415  dose may be adjusted before the next scheduled visit. Unscheduled visits between Visits 2, 
3, 4, and 5 are allowed as needed, at the discretion of the Inves tigator.  
At Visit 5, the Investigator will evaluate  the eligibility criter ia (see Section 9.2.3 ) for continuation 
into the subsequent Double -Blind Treatment Phase. For subjects eligible for the Treatment Phase, 
the optimal daily KP415 dose will be used as the daily KP415 dose (or matching placebo ) in the 
Treatment Phase . 
10.2. Study Drug Administration  in the Double -Blind Treatment Phase  
The following treatments will be administered in the Double -Blind Treatment Phase:  
• Treatment A: one KP415 capsule (test product ) once daily for 7 days.  
• Treatment B: one matching placebo capsule once daily for 7 days.  
The dose of KP415 will be determined by [CONTACT_728297]415  at the end of the Dose 
Optimization Phase, either 20, 30 or 40 mg/day KP415 or matching placebo.  
During the Treatment Phase, blinded study medications of each treatment will be administered from 
Sunday (the day after Visit 5) to Saturday (Visit 6). On Saturday (Visit 6) , the blinded doses of each 
study drug will be administered at the school site by [CONTACT_34450] y staff on the morning of the test laboratory 
classroom day. On the other days, the medication will be taken in the morning at home. Double -
blind study drug  will be taken  orally with 240 mL water and additional water may be given if needed  
10.3. Treatment Assign ment /Randomization  
Open -Label Dose  Optimization Phase : All eligible subjects will start on a dose of 30 mg/day 
open -label KP415  and the KP415  dose will be titrated to either 20, 30 or 40 mg/day based on 
tolerability and best individual dose -response in the opi[INVESTIGATOR_689].  
Double -Blind Treatment Phase:  Subjects able to tolerate at least 20 mg/day of KP415  and with 
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 40 of 81  April 6, 2018  
 an adequate dose -response during the Dose  Optimization Phase (see eligibility criteria in Section 
9.2.3 ) will be randomized on  Day 21 (Visit 5)  of the Treatment Period on a 1:1 basis to a treatment 
of KP415 (Treatme nt A) or placebo (Treatment B).  Randomization will be stratified by [CONTACT_3885].  
10.4. Blinding  
Open -Label Dose Optimization Phase : the KP415  dose levels during the Dose  Optimization 
Phase  including the optimized KP415  dose at the end of the Dose  Optimization Phase  will not be 
blinded.  
Double -Blind Treatment Phase:  the treatment with study drug, either active KP415 or placebo, 
will be blinded during the Double -Blind Treatment Phase . Neither the subject , the Investigator , or 
the Sponsor  will know the subject ’s treatment assignment.  
Upon completion of the study and aft er the database is locked according to the Sponsor (or designee) 
operating procedures, the randomization codes will be provided to the statistician to unblind the 
study.  
Emergency unblinding of patients : Under normal circumstances, the blind will not be b roken until 
subjects have completed treatment. The blind for individual subjects can be broken before study 
unblinding at the request of the Investigator only if a specific emergency treatment would be 
dictated by [CONTACT_355774] a subject.  When  knowledge of the patient’s treatment 
assignment is essential for the clinical management or welfare of the patient, the Investigator should 
contact [CONTACT_688950]’s Medical Monitor (or designee). Prior to unblinding the patient’s treatment 
assignment, the I nvestigator should assess the relationship of an adverse event to the administration 
of the study drug (Yes or No). The Investigator must then contact [CONTACT_688950]’s Medical Monitor to 
unblind an individual patient’s treatment assignment. If the blind is broken  for any reason, the 
Investigator must record the date and reason for breaking the blind on the appropriate electronic 
Case Report Form (eCRF) and source documents . If an SAE is reported, the ARO’s Medical 
Monitor (or designee)  may unblind the treatment as signment for an individual subject for expedited 
regulatory reporting requirements . 
10.5. Compliance  
All study drug will be recorded by [CONTACT_25733] ’s pharmacy staff member or Investigator -delegated 
employee. A record of the study drug accountability  will be prepared and kept by [CONTACT_977].  
11. STUDY PROCEDURES  
The study will consist of a Screening Visit , an Open -Label Dose Optimization Phase, a Double -
Blinded Treatment Phase , and a Follow -Up Visit.  A table with the Schedule of Events (SOE) 
represe nting the required testing procedures to be performed is included  in Section [ADDRESS_1247584] of these procedures and assessments:   
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 41 of 81  April 6, 2018  
 11.1. Screening Procedures  
Subjects will complete the screening visit (Visit 1) within 49 days of starting the Open -Label Do se 
Optimization Phase  (Visit 2 ). Prior to conducting any study -related activities  including screening 
procedures , written  or verbal  assent  and the Health Insurance Portability and Accountability Act 
(HIPAA) authorization must be  signed and dated by [CONTACT_626494]/legal guardian . 
The following procedures  will be performed at the Screening Visit:  
1. Permission  and HIPAA authorization  by [CONTACT_174964]/legal guardian of the subject . 
2. Written or verbal assent by [CONTACT_423] . For verbal assent, the procedure will be 
documented and signed by a witness. A parent or guardian may not be the witness for 
a child's verbal assent document.  
3. ADHD Diagnosis and Confirmation  based on the Statistical Manual of Mental 
Disorders - Fifth Edition (DSM -5) criteria for a primary diagnos is of ADHD 
(combined, inattentive, or hyperactive/impulsive presentation) and confirmed by [CONTACT_728298] (MINI -
KID) . 
4. Perform the clinician -administered Clinical Global Impressions –Severity (C GI-S) 
scale assessment.  Subject s must have a CGI-S score of at least 3 (mildly ill) for further 
study participation.  
5. Subject demographics including date of birth, sex, race, and ethnicity.  
6. Administer a size 3 capsule orally with 240 mL of water (Capsule Sw allowing Test).  
The capsule may not contain any active drug substance. Subjects must be able to easily 
swallow the size 3 capsule to be eligible for further study participation.  
7. Review of  inclusion/exclusion criteria to determine study  eligibility . 
8. Record medical  history  including chronic conditions, relevant surgical procedures 
(with start date), medications, and history of alcohol and  recreational drug use.  
9. A complete physical  exam ination . 
10. Body weight, height, and BMI.  
11. Vital signs after a minimum of [ADDRESS_1247585] (respi[INVESTIGATOR_697], pulse  rate, blood 
pressure, and oral temperature ). 
12. Perform the  Columbia Suicid e Severity Rating S cale ( C-SSRS ) assessment , 
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 42 of 81  April 6, 2018  
 “Children’s Baseline/Screening” version.  Subjects with a history of attempted suicide 
or clinical ly significant suicidal ideation based on the C -SSRS assessment, in the 
opi[INVESTIGATOR_891162], and further 
evaluation and/or preventive intervention steps for suicidal behavior will be taken, at 
the discr etion of the Investigator.  
13. 12-lead e lectrocardiogram  (ECG)  after subject  has been  in supi[INVESTIGATOR_19636]  a 
minimum  of 3 minutes . 
14. Clinical  laboratory  tests (chemistry, hematology and urinalysis ) will be obtained . 
Clinical laboratory measurements may be repeated at the discretion of the Investigator.  
15. At Screening, u rine samples will be tested for alcohol  and drugs of abuse 
(amphetamines, methamphetamines, benzodiazepi[INVESTIGATOR_1651], barbiturates, cannabinoids, 
cocaine, opi[INVESTIGATOR_355752]). If the urine test  is positive for alcohol  or drugs 
of abuse at Screening, the subject will be excluded from study participation, with the 
exception of the following: Depending on a subject's current ADHD medication at 
Screening, the urine screen at Screening may test posit ive for ADHD medications such 
as amphetamines  and metha mphetamines . These medications must be washed out by 
[CONTACT_2006] [ADDRESS_1247586] w ill be excluded from study 
participation, with the exception of the following: Depending on a subject's current 
ADHD medication at Screening, the urine screen at Screening may test positive for 
methylphenidate. S ince these medications must be washed out by  [CONTACT_2006] 0, the 
methylphenidate screen  must test negative on Day 0 (Visit 2) for subjects to be eligible 
to continue in the study . 
17. Serum β -human chorionic gonadotropin ( β-hCG) pregnancy test  for al l female subjects  
of childbearing potential . A positive pregnan cy test will exclude a subject from further 
participation in the study.  “Of childbearing potential” is defined in Section 1 4.8. 
18. Review of concomitant medications, treatment and/or therapi[INVESTIGATOR_891163].  
After subject s complete  the s creening procedures and are considered eligible to take part in the 
clinical study , they will be instructed to return to the clinic at Visit 2 to begin the  Open -Label Dose 
Optimization Phase.  In addition, they will be instructed with the date on which to begin wash out 
of any ADHD and other medications prior to Day 0 (Visit 2). See Section 12.1  for the medications 
that are prohibited and their associated time frames, including the days that they are prohibited 
before Day 0 (Visit 2), i.e., washout days for subjects taking the medications.  
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 43 of 81  April 6, 2018  
 Before or on the day during the screening period that subjects will need to start the washout of their 
ADHD medications  (for example, 5 days before Visit 2  for stimulants ), study site staff w ill contact 
[CONTACT_423] ’s parent /guar dian by [CONTACT_728299] (“washout phone call”) . 
Rescreening: Subjects who are screened outside the screening window may be rescreened for 
participation in a later cohort. Subjects who received any dose of study drug and are terminated 
early or are not eligible to continue in the Treatment Phase, are not eligible to participate in another 
cohort of the study (and will not be rescreened).  
11.2. Open -Label Dose Optimization Phase  (Visit 2 -5) 
Subjects who meet the inclusion/exclusion c riteria during Screening, will enter into the Open -Label 
Dose Optimization Phase (Visit 2 -5). The s ubjects will undergo the following procedures  during 
these visits . 
11.2.1.  Visit 2  (Day 0)  
The following procedures  will be performed at Visit 2 : 
1.  Review of inclusio n/exclusion criteria to determine whether subjects continue to meet 
study eligibility.  
2. A Placement Permanent Product Measure of Performance (PERMP) will be performed 
to assure that subjects can complete at least the basic level of math problems and to 
determine the appropriate level of math to be assigned during the practice laboratory 
classroom day at Visit 4. Subjects must be able to perform at least the basic level of 
problems to enroll in the trial.  
3. Update medical history.  
4. Vital signs after a minimum of  [ADDRESS_1247587] (respi[INVESTIGATOR_697], pulse  rate, blood 
pressure, and oral temperature ). 
5. Perform the Columbia Suicid e Severity Rating Scale (C-SSRS ), “Children’s Since Last 
Visit” version . Subjects with clinically significant suicidal ideation based on the C -
SSRS assessment, in the opi[INVESTIGATOR_689], will be exclude d from further 
participation in the study , and further evaluation and/or preventive intervention steps for 
suicidal be havior will be taken, at the discretion of the Investigator.  
6. Perform the ADHD -Rating Scale -5 (ADHD -RS-5) score (DuPaul et al.  2016 ) 
assessment  (baseline assessment) . Subjects needs to have an ADHD -RS-[ADDRESS_1247588] 5 days . 
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 44 of 81  April 6, 2018  
 7. Perform the clinician -administered Clinical Global Impressions –Severity (CGI -S) scale  
assessment  (baseline assessment ). Subject s must have a CGI-S score of at least 3 (mildly 
ill) for further study participation. For subjects requiring washout of ADHD 
medications, this criterion refers to a score following washout of at least 5 days . 
8. Perform the Clinical Global Impressions –Improve ment (CGI -I) scale assessment . 
9. Perform the Conners 3 -P baseline assessment . The parent/ guardian/ caregiver  will assess 
the subject’s ADHD sympt oms using the Conners [ADDRESS_1247589]’s functioning on the days before Visit 2 (and since washout of ADHD 
medications, if applicable) . 
10. Perform the Weekly Rating of Evening and Morning Behavior - Revised (WREMB -R) 
assessment. T he Investigator or designee will fill in the WREMB -R questionnaire based 
on an interview with the parent/ guardian/caregiver . The scoring will be based on the 
subject’s morning and evening functioning on the days before Visit 2 (and after washout 
of ADHD medications, if applicable).  
11. Urine samples will be tested for methylphenidate. If the urine test is positive 
methylphenidate on Day 0, the subject will be excluded from study participation . 
12. Urine pregnancy test for all female subjects  of childbearing potential . A positive 
pregnancy test at Screening will exclude a subject from further participation in the study.  
“Of childbearing potential” is defined in Section 1 4.8. 
13. Review of concomitant medications, treatment and/or therapi[INVESTIGATOR_014].  
14. Assessment and review of Adverse Events, and the subject’s parent/guardian will be 
instructed to contact [CONTACT_728300].  
15. Provide subject with the starting dose of 30 mg KP415  to begin the Dose Optimization 
Phase (Days 1 -7 ±3 days ). KP415  dose adjustments, if needed, will be performed at 
approximately weekly intervals  between visits (at Visits 3  and 4) . Actual visit dates may 
deviate from exactly being spaced 7 days apart such that the total duration of the Dose 
Optimization Phase ranges betw een 18 and 24 days (21 ±3 days) . 
11.2.2.  Visit 3  (Day 7  ±3 days ) 
The following procedures  will be performed at Visit 3: 
1. Record the number of returned and administered capsules of unblinded study drug for 
drug accountability and compliance . 
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 45 of 81  April 6, 2018  
 2. Review of inclusion/exclusion criteria to determine whet her subjects continue to meet 
study eligibility.  
3. Update medical history . 
4. Vital signs after a minimum of [ADDRESS_1247590] (respi[INVESTIGATOR_697], pulse rate, blood 
pressure, and oral temperature) . 
5. Perform the Columbia Suicide Severity Rating Scale (C -SSRS), “Children’s Since Last 
Visit” version . Subjects with clinically significant suicidal ideation based on the C -
SSRS assessment, in the opi[INVESTIGATOR_689],  will be exclude d from further 
participation in the study , and further evaluation and/or preven tive intervention steps for 
suicidal behavior will be taken, at the discretion of the Investigator.  
6. Perform the ADHD -Rating Scale -5 (ADHD -RS-5) score (DuPaul et al. 2016 ) 
assessment.  
7. Perform the clinician -administered Clinical Global Impressions –Severity ( CGI-S) scale 
assessment.  
8. Perform the Clinical Global Impressions –Improvement (CGI -I) scale assessment.  
9. Perform the Conners 3 -P Assessment. The parent/ guardian/ caregiver  will assess the 
subject’s changes in ADHD sympt oms using the Conners 3 -P questionnaire . 
10. KP415 dosing and dose adjustments, if needed, will be performed at wee kly intervals ± 
3 days. At Visit 3 , based on the CGI, interview with the parent /guardian/ caregiver , and 
safety data, the I nvestigator will evaluate the subject’s therapeutic responses and 
tolerability to treatment, and decide whether the current KP415  dose should be 
increased, decreased, or remain the same for the next week of titration . At any day during 
the Dose Optimizatio n Phase, the daily dose will be either 20, [ADDRESS_1247591]’s parent/guardian will be 
instructed to contact [CONTACT_728300] . 
12. Review of con comitant medications, treatment and/or therapi[INVESTIGATOR_014].  
11.2.3.  Visit 4  (Day 14 ±3 days)  
If possible, study site staff will contact [CONTACT_7071]/guardian [ADDRESS_1247592] come to Visit 4 without taking the study drug since it will be administered by [CONTACT_869216] 4.  
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 46 of 81  April 6, 2018  
 The following procedures  will be performed at Visit 4: 
1. Record the number of returned and administered capsules of unblinded study drug for 
drug accountability and compliance . 
2. Review of inclusion/exclusion criteria to  determine whether subjects continue to meet 
study eligibility.  
3. Update medical history . 
4. Vital signs after a minimum of [ADDRESS_1247593] (respi[INVESTIGATOR_697], pulse rate, blood 
pressure, and oral temperature) . 
5. Perform the Columbia Suicide Severity Rating Scal e (C-SSRS), “Children’s Since Last 
Visit” version . Subjects with clinically significant suicidal ideation based on the C -
SSRS assessment, in the opi[INVESTIGATOR_891164] d from further 
participation in the study , and further evaluation and/or preventive intervention steps for 
suicidal behavior will be taken, at the discretion of the Investigator.  
6. Perform the ADHD -Rating Scale -5 (ADHD -RS-5) score (DuPaul et al. 2016) 
assessment.  This assessment may be obtained by [CONTACT_1382] 48 hours bef ore the visit.  
7. Perform the clinician -administered Clinical Global Impressions –Severity (CGI -S) scale 
assessment.  This assessment may be obtained by [CONTACT_1382] 48 hours before the visit . 
8. Perform the Clinical Global Impressions –Improvement (CGI -I) scale as sessment.  This 
assessment may be obtained by [CONTACT_1382] [ADDRESS_1247594] -dose.  
11. Perform the Conners 3 -P Assessment. The  parent/ guardian/ caregiv er will assess the 
subject’s changes in ADHD sympt oms using the Conners 3 -P questionnaire . The 
questionnaire form may be provided to the parent/ guardian/ caregiver at the previous 
visit, and be filled in by [CONTACT_7071]/ guardian/ caregiver before coming to thi s visit.  
12. KP415 dosing and dose adjustments, if needed, will be performed at wee kly intervals 
±3 days . At Visit 4, based on the CGI, interview with the parent /guardian/ caregiver , and 
safety data, the I nvestigator will evaluate the subject’s therapeutic responses and 
Protocol KP415.E01 Amendment #[ADDRESS_1247595]’s parent/guardian will be 
instructed to contact [CONTACT_728300] . 
14. Review of concomitant medications, treatment and/or therapi[INVESTIGATOR_014].  
11.2.4.  Visit 5  (Day 21  ±3 days ) 
Two days before Visit 5, subjects must not take any study drug  (this is important for obtaining a 
baseline of the SKAMP/PERMP scores). At Visit 5, subjects will be administered u nblinded study 
drug at the study site (this is the last dose of unblinded study drug ). If possible, study site staff will 
contact [CONTACT_7071]/guardian [ADDRESS_1247596] abstain of taking 
study drug on the 2 days before Visit 5, and come to Visit 5 without taking the study drug since it 
will be administered by [CONTACT_277117] 5.  
The following procedures will be performed at Visit 5 : 
1. Record the number of returned and administered capsules of unblinded study drug for 
drug accountability and compliance .  
2. Update medical history.  
3. Vital signs after a minimum of [ADDRESS_1247597] (respi[INVESTIGATOR_697], pulse rate, blood 
pressure, and oral temperature).  
4. Urine pregnancy test for all female subjects of childbearing potential . A positive 
pregnancy test will exclude a subject from further participation in the study.  “Of 
childbearing potential” is defined in Section 1 4.8. 
5. Urine samples will be tested for methylphenidate . 
6. Perform the Columbia Suicide Severity Rating Scale (C -SSRS)  assessment , “Children’s 
Since Last Visit” version . Subjects with clinically significant suicidal ideation based on 
the C -SSRS assessment, in the opi[INVESTIGATOR_689],  will be exclude d from further 
participation in the study , and further evaluation an d/or preventive intervention steps for 
suicidal behavior will be taken, at the discretion of the Investigator.  
7. Administer the open -label KP415 dose at the laboratory school by [CONTACT_464]. The 
capsule with study drug will be swallowed with  approximately 24 0 mL of water. 
Protocol KP415.E01 Amendment #[ADDRESS_1247598] -dose.  The 
pre-dose SKAMP and PERMP assessments will be recorded as the baseline for these 
assessments.  
9. Perform the ADHD -Rating Scale -5 (ADHD -RS-5) score (DuPaul et al.  2016 ) 
assessment.  This assessment may be obtained by [CONTACT_1382] 48 hours before the visit.  
This assessment will be made based on the days before Visit 5 while still taking study 
drug (and NOT based on the 2 days of no study drug before Visit 5).  
10. Perform the clinician -administered Clinical Globa l Impressions –Severity (CGI -S) scale 
assessment.  This assessment may be obtained by [CONTACT_1382] 48 hours before the visit.  
This assessment will be made based on the days before Visit 5 while still taking study 
drug (and NOT based on the 2 days of no study  drug before Visit 5).  
11. Perform the Clinical Global Impressions –Improvement (CGI -I) scale assessment.  This 
assessment may be obtained by [CONTACT_1382] 48 hours before the visit . This assessment 
will be made based on the days before Visit 5 while still taking  study drug (and NOT 
based on the 2 days of no study drug before Visit 5).  
12. Perform t he Conners 3 -P Assessment.  At this visit, t he parent/ guardian/ caregiver  will 
assess the subject’s changes in ADHD sympt oms using the Conners [ADDRESS_1247599]’s functioning on the days before Visit 5 while still taking study 
drug (and NOT based on the 2 days of no study drug before Visit 5) . The questionnaire 
form may be provided to the parent/ guardian/ caregiver at the previous visit, and be filled 
in by  [CONTACT_7071]/ guardian/ caregiver before coming to this visit.  
13. Perform the Weekly Rating of Evening and Morning Behavior - Revised (WREMB -R) 
assessment. T he Investigator or designee will fill in the WREMB -R questionnaire based 
on an interview with the parent/ guardian/caregiver.  The scoring will be based on the 
subject’s morning and evening functioning on the days  before Visit 5 while still taking 
study drug (and NOT based on  the 2 days of no study drug before Visit 5 ). 
15. The Investigator will evaluate the eligib ility criteria (see Section 9.2.3 ) for continuation 
into the subsequent Double -Blind Treatment Phase. For subjects eligible for the 
Treatment Phase, the optimal daily KP415 dose will be used as the daily KP415 dose 
(or matching placebo) in the Treatment Ph ase. 
14. Randomize subjects on a 1:1 basis to  a treatment of KP415 (Treatme nt A) or placebo 
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 49 of 81  April 6, 2018  
 (Treatment B). The appropriate blinded study drug to be taken at home once -a-day in 
the morning on each of the following 6 days (Days 22 -27 ±3 days ) will be dispensed t o 
the subjects.  
15. Assessment  and review of  Adverse Events , and the s ubject’s parent/guardian will be 
instructed to contact [CONTACT_728300] . 
16. Review of concomitant medications, treatment and/or therapie s. 
11.2.5.  Unscheduled Visits  
At the discretion of the Investigator, subjects may be asked to come to the clinical site for an 
unscheduled visit. Unscheduled visits can occur at any time during the Dose Optimization Phase, 
between Visits 2, 3, [ADDRESS_1247600] an unscheduled visit:  
• If subjects experience an Adverse Event during the at -home treatment, they must contact 
[CONTACT_977], and, at the discretion of the Investigator, further in -person medical 
evaluation and review is needed.  
• If subjects experience symptoms of intolerance during the at -home treatment  with study 
drug or have complaints about increases  in ADHD sympt oms, they must contact [CONTACT_31871], and, at the discretion of the Investigator, their KP415 dose may be adjusted b efore the 
next scheduled visit.  
The following procedures will occur at the Unscheduled Visit:  
1. Record the number of administered capsules of unblinded study drug for drug 
accountability and compliance . For this purpose, subjects will be asked to bring their  
unused medication to the clinical site.  
2. Vital signs after a minimum of [ADDRESS_1247601] (respi[INVESTIGATOR_697], pulse rate, blood 
pressure, and oral temperature).  
3. Assessment  and review of Adverse Events.  
4. Review of concomitant medications, treatment and/or the rapi[INVESTIGATOR_014].  
The following procedures will occur at the Unscheduled Visit , each at the discretion of the 
Investigator : 
1. Evaluations for safety, as needed (for example, to evaluate and review Adverse Events):  
a. Physical examination  
Protocol KP415.E01 Amendment #[ADDRESS_1247602] has bee n in supi[INVESTIGATOR_19636] a minimum of 3 
minutes  
c. C-SSRS, “Children’s Since Last Visit” version . Subjects with clinically 
significant suicidal ideation based on the C -SSRS assessment, in the opi[INVESTIGATOR_15960], will be exclude d from further particip ation in the study , and 
further evaluation and/or preventive intervention steps for suicidal behavior will 
be taken, at the discretion of the Investigator.  
d. Clinical laboratory assessments  
2. If, at the discretion of the Investigator, an unscheduled evaluation  of the changes  in 
ADHD symptoms is needed, for a potential unscheduled  dose level change of unblinded 
KP415 drug : 
a. Perform the CGI-I scale assessment.  
b. Perform the Conners 3 -P Assessment. The parent/ guardian/ caregiver  will assess 
the subject’s changes in AD HD sympt oms using the Conners 3 -P questionnaire . 
c. If needed, perform a KP415 dose adjustments:  based on the CGI, interview with 
the parent /guardian/ caregiver , and safety data, the Investigator will evaluate the 
subject’s therapeutic responses and tolerability to treatment, and decide whether 
the current KP415  dose should be increased, decreased, or remain the same . At 
any day during the Dose Optimization Phase, the daily dose will be  either 20, [ADDRESS_1247603] will be withdrawn 
and Early Termination procedures will be completed  (see Section 11.4 ). At the discretion of the 
Investigator, ensuring the saf ety of the subjects, any ET procedures that were already performed on 
the same day as part of the Unscheduled Visit  do not need to be repeated.  
11.3. Treatment Phase : Days 22-27 & Visit 6 ( Day 28) 
On Days 22 -27 ±[ADDRESS_1247604]’s parent/guardian will contact [CONTACT_891177] e dosing period  at home . 
The final dose of double -blind study drug will be administered on the 7th day of the double -blind 
Treatment Phase (Day 28  ±3 days ; Visit 6) at the laboratory school by [CONTACT_464]. On Day 28  ±3 
days (Visit 6), each subject will complete a full -length laboratory classroom day with efficacy 
assessments at pre -dose and post -dose s tudy drug.  
The following procedures will occur on Day 28  ± 3 days  (Visit 6) of the study : 
1. Record the number of returned and administered capsules of blinded study drug for dru g 
accountability and compliance . 
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 51 of 81  April 6, 2018  
 2. Vital signs (respi[INVESTIGATOR_697], pulse rate, bloo d pressure, and oral temperature) after 
subject has been sit ting for a minimum of 3 minutes, will be collected at any time before 
dosing.  
3. Perform the Columbia Suicide Severity Rating Scale (C -SSRS)  assessment , “Children’s 
Since Last Visit” version . At Visi t 6, if a subject has clinically significant suicidal 
ideation based on the C -SSRS assessment, in the opi[INVESTIGATOR_689] , further 
evaluation and/or preventive intervention steps for suicidal behavior will be taken, at the 
discretion of the Investi gator.  
4. Perform the Weekly Rating of Evening and Morning Behavior - Revised (WREMB -R) 
assessment. T he Investigator or designee will fill in the WREMB -R questionnaire based 
on an interview with the parent/ guardian/caregiver.  The scoring will be based on the 
subject’s morning and evening functioning on the days  before Visit [ADDRESS_1247605] will complete a full -length laboratory classroom day with efficacy 
assessments , as listed below . 
6. Perform the Conners 3 -P Assessment. At Visit  6, the parent/ guardian/ caregiver  will 
assess the subject’s changes in ADHD sympt oms using the Conners 3 -P questionnaire . 
7. Administer the final dose of the double -blind study drug on the 7th day of the Double -
Blind Treatment Phase  at the laboratory school b y study staff. The capsule with study 
drug will be swallowed with  approximately 240 mL of water. Additional water may be 
given if needed, and the volume of additional water will be recorded . 
8. Perform the  (SKAMP) Swanson, Kotkin, Agler, M -Flynn, and Pelham  score 
assessments at pre -dose and at 0.5, 1, 2, 4, 8, 10, [ADDRESS_1247606] Measure of Performance  (PERMP)  score assessment  
at pre-dose and at 0.5, 1, 2, 4, 8, 10, [ADDRESS_1247607] -dose on the full classroom 
day. 
10. Review of concomitant medications, treatment and/or therapi[INVESTIGATOR_014].  
11. Assessment  and review of Adverse Events.  
11.4. Early Termination Visit  
Early Termination (ET) from the study is defined as withdrawal during the Dose Optim ization 
Phase or Treatment Phase after at least one dose of study drug is administered. For subjects who 
Protocol KP415.E01 Amendment #[ADDRESS_1247608] from the research clinic.  
The following procedures will be performed at ET visits:  
1. Complete physical examination.  
2. Body weight.  
3. Vital signs (respi[INVESTIGATOR_697], pulse rate, blood pressure, and oral temperature) after subject 
has been sitting for a minimum of [ADDRESS_1247609] has been in supi[INVESTIGATOR_19636] a minimum of 3 minutes.  
5. Clinical laboratory tests (chemistry, hematology an d urinalysis).  
6. Urine pregnancy test for all female subjects  of childbearing potential . “Of childbearing 
potential” is defined in Section 1 4.8. 
7. Assessment of the Columbia Suicide Severity Rating Scale (C -SSRS), “Children’s Since 
Last Visit” version.  If a subject has clinically significant suicidal ideation based on the C -
SSRS assessment, in the opi[INVESTIGATOR_689],  further eva luation and/or preventive 
intervention steps for suicidal behavior will be taken, at the discretion of the Investigator.  
8. Review of concomitant medications, treatment and/or therapi[INVESTIGATOR_014].  
9. Assessment  and review  of Adverse Events.  
Subjects will be discharged from the study clinic when the Investigator determines that the subjects 
are medically stable and, if possible, after all ET procedures are completed.  
Subjects who withdraw early from the study and complete the above ET procedures will not return 
for a Fol low-Up Visit. Therefore, the ET Visit is the EOS for these subjects.  
11.5. Follow -Up Visit  
Subjects who complete the all phases of the study from the Open -Label Dose Optimization Phase 
through the Treatment Phase will return in 3 ±[ADDRESS_1247610] dose of 
study drug for the Follow -Up Visit.  
The following procedures will be completed during the Follow -Up Visit:  
1. Complete physical examination.  
2. Body weight.  
Protocol KP415.E01 Amendment #[ADDRESS_1247611] (respi[INVESTIGATOR_13521] y rate, pulse rate, blood pressure, 
and oral temperature).  
5. 12-lead ECG after subject has been in supi[INVESTIGATOR_19636] a minimum of 3 minutes.  
6. Clinical laboratory tests (chemist ry, hematology and urinalysis).  
7. Urine pregnancy test for all female subjects  of childbearing potential . “Of childbearing 
potential” is defined in Section 1 4.8. 
8. Assessment of the Columbia Suicide Severity Rating Scale (C -SSRS), “Children’s Since 
Last Visit” version . If a subject has clinically significant suicidal ideation based on the C-
SSRS assessment, in t he opi[INVESTIGATOR_689],  further evaluation and/or preventive 
intervention steps for suicidal behavior will be taken, at the discretion of the Investigator.  
9. Review of concomitant medications, treatment and/or therapi[INVESTIGATOR_014].  
10. Assessment  and review  of adverse events.  
The Follow -Up Visit is the EOS for subjects who will undergo the Follow -Up procedures.  
11.6. End of Study (EOS)  
The End of Study (EOS) is either the Follow -Up Visit for subjects who complete the Treatment 
Phase, or the Ea rly Termination Visit for subjects who  withdraw early from the study.  
12. CONCOMITANT MEDICATIONS AND RESTRICTIONS  
Subjects will adhere to th e following restrictions before  and after administration of study drug , as 
specified : 
12.1. Medication  Restrictions  
• Stimulant  ADHD medications (with the exception of study drug), including herbal 
medications, are prohibited from 5 days prior to the start of the Dose Optimization Phase 
(Day 0) to the end of the Follow -Up Visit or Early Termination Visit. These include: 
methylphen idate, amphetamine, Ritalin®, Ritalin® SR, Metadate® ER, Concerta®, 
dextromethylphenidate, Focalin®, dextroamphetamine, Dexedrine®, Adderall®. 
• Non-Stimulant ADHD medications are prohibited from 21 days prior to the start of the Dose 
Optimization Phase (Day  0) to the end of the Follow -Up Visit or Early Termination Visit. 
These include: Atomoxetine, guanfacine, clonidine; and SSRIs such as fluoxetine and 
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 54 of 81  April 6, 2018  
 paroxetine.  
• The following medications are prohibited from 21 days prior to the start of the Dose 
Optimizat ion Phase (Day 0) to the end of the Follow -Up Visit or Early Termination Visit:  
o Tricyclic antidepressants.  
o Monoa mine oxidase inhibitors (MAOIs)  
o Mood stabilizers (e.g., lithium, valproate, quetiap ine) 
o Antipsychotics (e.g., risperidone, olanzapi[INVESTIGATOR_050])  
o Coumarin anticoagulants  
o Anticonvulsants  
o Halogenated anesthetics  
o Phenylbutazone  
o Coumarin anticoagulants  
 
• Sedative hypnotics/sleep enhancers (with the exception of melatonin) are prohibited from 
14 days prior to the start of the Dose Optimization Phase (Day 0) to the  end of the Follow -
Up Visit or Early Termination Visit.  
• Melatonin is allowed if subjects have taken it for more than 30 days before the start of the 
Dose Optimization Phase (Day 0) and are on a stable dose. Otherwise, m elatonin is 
prohibited from 5 days pr ior to Day 0  to the end of the Follow -Up Visit or Early Termination 
Visit.  
Medications allowed during the course of the study include nasal steroids, bronchodilators, 
acetaminophen and nonsteroidal anti -inflammatory medications; non -sedating antihistamines  such 
as cetirizine, loratadine, and fexofenadine; mometasone; and approved courses of prescription and 
nonprescription medications for the treatment of acute illnesses . 
12.2. General Restrictions  
Female subjects must agree when they are of childbearing potentia l at Screening or when they 
become of childbearing potential during the study, to remain abstinent or agree to use an effective 
and medically acceptable form of birth control from the time of written or verbal assent to at least 
[ADDRESS_1247612] dos e of study drug has been taken.  
“Of childbearing potential” is defined in Section 1 4.8. 
Protocol KP415.E01 Amendment #[ADDRESS_1247613]  
13.1. Active Pharmaceutical Ingredients  
The chemical name [CONTACT_4007] t he KP415 prodrug is 3-(((S) -1-carboxy -2-hydrox yethyl)carbamoyl) -1-
((((R) -2-((R)-2-methoxy -2-oxo-1-phenylethyl)pi[INVESTIGATOR_119510] -1-carbonyl)oxy)methyl) pyridine -1-ium 
chloride. It is a single d -methylphenidate molecu le covalently attached via a carbamate bond to a 
methylene oxide linker which in turn is connected to the nitrogen of the pyridine ring of a 
nicotinoyl -serine moiety.  
13.2. Clinical Trial Material  
The capsules of study drug (KP415 capsules) with contain two acti ve pharmaceutical ingredients: 
d-methylphenidate hydrochloride as the immediate release  (IR) d-methylphenidate component, and 
KP415 prodrug as the extended release  (ER)  d-methylphenidate component. In terms of d -MPH  
equivalent amounts , all capsule st rength s contain 30% of d -MPH (IR component) and 70% of d -
MPH from the KP415 prodrug.  The total equivalent amount of d -methylphenidate (d -MPH) in each 
capsule strength (used as daily doses in this study), and the amounts of both APIs are listed in the 
following t able.  
Total  
d-MPH 
dose 1 
(mg)  d-MPH  2 
 
 
(mg)  KP415  
Prodrug 3 
 
(mg)  
20 6 28 (14) 
30 9 42 (21)  
40 12 56 (28)  
1. Based on the d -MPH amount plus the equivalent amount of d -MPH as KP415 prodrug.  
2. The dose of d -MPH is expressed in terms of d -methylphenidate hydrochloride . 
3. The dose of KP415 prodrug is expressed in terms of KP415 chloride . The amount of d-MPH  hydrochloride  
equimolar to each KP415 prodrug dose  is listed between parentheses.  
 
Unblinded capsules with 20, 30 and 40 mg KP415 will be used in the Open -Label Dose 
Optimization Phase; capsules of 20, 30 and 40 mg KP415 blinded versus placebo capsules will be 
used in the Double -Blind Treatment Phase. All study drug will be supplied by t he Sponsor (or 
design ee). The Sponsor (or designee) will supply sufficient quantities of KP415 and placebo to 
allow for completion of the study. The study drug shipment(s) will be shipped to each site after site 
activation (i.e., after all required regulat ory documentation has been received by [CONTACT_891178] a contract has been executed).  The lot numbers of study drug supplied will be recorded 
in the study report.  
All other drug products needed for the conduct of the study will be commercially available products 
obtained by [CONTACT_728306].  
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 56 of 81  April 6, 2018  
 13.3. Pharmaceutical Formulation  
KP415 and placebo are provided in size 3 capsules consisting of an opaque white hydroxy propyl 
methylcellulose (HPMC) capsule shell without markings.  Besides KP415 drug substance,  each 
capsule of double -blind  study drug contains the following inactive ingredients: microcrystalline 
cellulose, crospovidone, colloidal silicon dioxide, and magnesium stearate. The placebo capsules 
contain microcrystalline cellulose . 
13.4. Packaging and  Labeli ng 
The KP415 capsules for the Open-Label Dose Optimization Phase, and the KP415 and placebo 
capsules for the Double -Blind Treatment Phase will be packaged and labeled appropriately.  
13.4.1.  Open -Label Dose Optimization Phase  
Unblinded  KP415 capsules will be packag ed as bottle s with [ADDRESS_1247614] 7 days of dosing in the Open -Label  Dose Optimization  
Phase ( 1 capsule/day) and 3 extra capsule s to cover the potential loss of capsule s or extra dosing 
days before the next visit . Each bottle  will be dispensed with  instructions on how to administer 
study drug. The number on the bottle will be recorded in the Electronic Data Capture (EDC) system 
for the study.  
13.4.2.  Double -Blind Treatment Phase  
Blinded study med ication will b e packaged and numbered as a  kit for each subject  based on the 
randomization scheme. The patient randomization number assigned by [CONTACT_891179]/process will correspond to the number on  the kit.  
Each kit  for the Double -Blind Treatment Phase will consist of 1 bottle with 10 capsules of study 
drug and 1 bottle with 1 capsule  of study drug . The bottle with 10 capsules contains  enough drug 
supply for 6 days of dosing at home in the Double -Blind Treatment Phas e (1 capsule/day  every 
morning ) and 4 extra capsule s to cover the potential loss of capsule s or extra dosing days before the 
next visit . The bottle with 1 capsule contains the capsule that will be administered in the research 
clinic in the morning of the l aboratory classroom day on Day 7 (Visit 6). This is the last and final 
dose of study drug.  
Each bottle  with 10 capsules will be dispensed to the subjects at Visit 5 with instructions on how to 
administer the study drug. The number  on the bottle will be recorded in the Electronic Data Capture  
(EDC) system for the study.  The bottle with 1 capsule will be labeled with the same number, and 
will be kept at the research clinic until administration.  
The bottle s of study drug will be labeled according to  the appropriate FDA regulations.  
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 57 of 81  April 6, 2018  
 13.5. Dispensing Procedures  
13.5.1.  Open -Label Dose Optimization Phase  
Unblinded bottles of drug supply will be dispensed at each visit as follows:  
• Visit 2:  At Visit 2, subjects will be dispensed an unblinded bottle with 10 capsules of 30 mg 
KP415 (starting dose).  
• Visit 3: Subjects will return to the research clinic after 7 ±3 days for Visit 3 with unused 
study drug, and will be dispensed either a bottle with 30 mg KP415 (same daily dose as 
Week 1), with 20 mg KP415 (dose level decrease from Week 1), or with 40 mg KP415 
(dose level increase from Week 1).  
• Visit 4:  Subjects will return to the research clinic after 7 ±3 days for Visit 4 with unused 
study drug, and will be dispensed either a bottle with 20 , 30 or 40  mg KP415 ( same daily 
dose as Week 2, or either dose level decrease or increase from Week 2 ). 
At Visits 2, [ADDRESS_1247615]’s parent or guardian with instructions 
when and how to administer study drug while at home, under supervision of parent or le gal 
guardian.  At each visit, site personnel will record the number of returned and administered capsules 
of unblinded study drug for drug accountability and  compliance . 
At Visits 4  and 5, subjects will be administered unblinded study drug at the study site . During the 2 
days before Visit 5, subjects will not take any study drug.  
13.5.2.  Double -Blind Treatment Phase  
Blinded bottles of drug supply (KP415 capsules or matching placebo) will be dispensed at each visit 
as follows:  
• Visit 5:  Subjects will return to the research clinic after 7 ±3 days after Visit 4, with unused , 
unblinded study drug.   
o At Visit 5, subjects will be administered unblinded study drug at the study site  (this 
is the last dose of unblinded study drug). During the 2 days before Visit 5, subjects 
will not take any study drug (this is important for obtaining a baseline of the 
SKAMP/PERMP scores).  
o At Visit 5, subjects will be assigned double -blind study drug by [CONTACT_891180]/process. The assigned study drug will consist of 
one of the following: 20, 30 or 40 mg KP415 capsules or placebo capsules. The 
bottle (bottle with 10 capsules) will be dispensed to the study  subject’ s parent or 
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 58 of 81  April 6, 2018  
 guardian with instruction s when and how to administer study drug  while at home, 
starting on the day after Visit 5 (Day 22) . On Days 22 -27, subjects will take study 
drug at home under supervision of parent or legal guardian . 
• Visit 6:  Subject’s p arent or guardian will be instructed to return for Visit [ADDRESS_1247616] day of the Double -
Blind Treatment Phase (Visit 6) at the laboratory school by [CONTACT_464].  One capsule from 
the second bottle in the drug supply kit (bottle with 1 capsule) will be used for  
administration.  Special care will be taken to assure that subjects receive the same  assigned  
study drug , during the days  at home and at the laboratory classroom day.  
At each vis it, a bottle will be dispensed to the subject’s parent or guardian with instructions when 
and how to administer study drug while at home, under supervision of parent or legal guardian. At 
each visit, site personnel will record the number of returned and ad ministered capsules of unblinded 
(at Visit 5) and blinded (at Visit 6) study drug for drug accountability and compliance . 
In the event that subjects report lost study drug during the at -home dosing period s, they will be 
instructed to contact [CONTACT_891181] a s possible after the loss. Lost drug supply may be 
replaced with the appropriate new bottle after the Investigator or designee contacts the interactive 
web response system or similar system/process. All efforts will be made to ensure  subjects rec eive 
daily doses of double -blind study drug for at least 7 days during the Double -Blind Treatment Phase.  
The Investigator will not supply study drug to anyone other than those named as sub -investigators 
on FDA Form 1572, designated site staff, and subjects  in the study.  
13.6. Storage of Study Drug  
Study drug will be stored at controlled room temperature 20° -25°C (68° -77°F) with excursions 
allowed between 15° and 30°C (59° and 86°F). Transient spi[INVESTIGATOR_201164] 40°C are permitted as long 
as they do not last for more th an [ADDRESS_1247617](s) must be stored as indicated. Deviations from the storage 
requirements, including any actions taken, must be documented and reported to the Sponsor . Once 
a deviation is identified, the investigational product must be quarantined and not used until the 
Sponsor provides documentation of permission to use the investigational product.  
Protocol KP415.E01 Amendment #[ADDRESS_1247618]. The study monitor will verify these documents 
throughout the course of the study.  
14. SAFET Y AND EFFICACY ASSESS MENT S 
14.1. Medical History  
A complete medical history will be obtained at the Screening Visit includ ing the recording of 
demographic data ( date of birth, sex, age, race, e thnicity ), collection of previous surgeries, 
medications and chronic conditions, past or present illnesses or dysfunctions, substance/drug abuse, 
and history of allergies or idiosyncratic responses to drugs.  Medical history (changes from 
screening) will be  updated at subsequent visits after the Screening Period.  
14.2. Physical Examination  
A complete physical examinat ion including body weight ( lbs or kg) will be completed for all 
subjects  at Screening, and at Early Termination  (if possible) or  Follow -Up. The complete physical 
examination will include a review of the subject’s general appearance, skin, head and neck (eyes, 
ears, nose, mouth, and throat), lymph nodes, thyroid, musculoskeletal/ extremities, cardiovascular 
system, lungs, abdomen and a brief exa mination of the neurological system.  
Height will be recorded in inches (in) or centimeters (cm) with the subject’s shoes removed. Body 
weight will be measured in pounds (lbs)  or kilograms (kg) ; subjects will remain in their normal 
clothing with shoes and j acket (and /or outer clothing) removed.  
14.3. ADHD  Diagnosis  and Severity Assessments  
At Screening, eligible subjects must meet the inclusion criteria for a primary diagnosis of ADHD  
by [CONTACT_170501] - Fifth Edition (DSM -5) criteria for a 
primary diagnosis of ADHD (combined, inattentive, or hyperactive/impulsive presentation) per 
clinical evaluation and confirmed by [CONTACT_891182] (MINI -KID).  
The following scale s will be used during the Open -Label Dose Optimization Phase to globally 
assess the changes in ADHD severity from week to week:  
• ADHD -Rating Scale -5 (ADHD -RS-5): The ADHD -RS-5 is an 18 -item scale based on 
Diagnostic and Statistical Manual of Mental Disorder s, 5th edition (DSM -5) (American 
Psychiatric Association 2013) criteria of ADHD that rates symptoms on a 4 -point scale. 
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 60 of 81  April 6, 2018  
 Each item is scored using a combination of severity and frequency ratings from a range of 
0 (reflecting no symptoms or a frequency of ne ver or rarely) to 3 (reflecting severe 
symptoms or a frequency of very often), so that the total ADHD -RS-5 scores range from 0 
to 54. The 18 items can be divided into two 9 -item subscales: One for 
hyperactivity/impulsivity and the other for inattentiveness . Scores will be obtained during 
a clinician -directed interview with the parent/ guardian/ caregiver  at each visit  in the Dose 
Optimization Phase . 
• Clinical Global Impressions –Severity (CGI -S): The CGI -S is a clinician -rated scale that 
evaluates the severity of psychopathology (ADHD symptoms in the study) on a scale from 
1 (not at all ill) to 7 (among the most severely ill) (Busner and Targum 2007).  
• Clinical Global Impressions –Improvement (CGI -I): The CGI -I is scored from 1 (very 
much improved) to 7 (very much worse).  
The following scale  will be used to assess the effect  of open -label KP415 during the Open -Label 
Dose Optimization Phase and the efficacy of KP415 ver sus placebo during  the D ouble -Blind 
Treatment Phase:  
• Conners 3 rd Edition -Parent (Conners 3 -P): The Conners 3 -P (short form) is a 43-item 
parent /guardian /caregiver  report that provides evaluation of inattention, 
hyperactivity/impulsivity, learning problems, executive functioning, aggression , and peer 
relationships. The parent/ guardian/ caregiver  will assess changes in ADHD symptoms via 
the Conners 3 -P questionnaire at baseline  (Visit 2 , Day 0 ) and at each visit during the Dose -
Optimization and the Treatment Phase . 
• Weekly Rating of Evening and  Morning Behavior - Revised (WREMB -R) Scale:  The 
11-item WREMB -R questionnaire is a parent -rated questionnaire that was developed to 
assess behaviors for their severity during the morning hours (3 items) and evening hours (8 
items)  (Carlson 2007) . The poss ible score for each item ranges from 0 (no difficulty) to 3 (a 
lot of difficulty). The Investigator or designee will obtain the scores for the WREMB -R 
questionnaire by [CONTACT_301288]/guardian/caregiver at Visits 2, 5 and 6. The 
assessment at Visit  2 is the baseline assessment (after washout of ADHD medications, if 
applicable); the assessments at Visits 5 and 6 are evaluations at the end of the Dose 
Optimization and Treatment Phase, respectively . 
The following scales will be used to assess the effic acy of KP415 versus placebo during the Double -
Blind Treatment Phase:  
• Swanson, Kotkin, Agler, M -Flynn, and Pelham (SKAMP) : Rating scale will be 
performed at Visit 4, Visit 5, and Visit 6.  
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 61 of 81  April 6, 2018  
 The SKAMP scale is a validated rating of subjective impairment of cla ssroom behaviors. It 
is comprised of 13 items (grouped under the subcategories of attention, deportment, quality 
of work, and compliance) on which subjects are rated according to a 7 -point scale (0 = 
normal to 6 = maximal impairment) by [CONTACT_891183] ( Swanson 1999 ). The 
SKAMP -Combined (SKAMP -C) score is obtained by [CONTACT_891184] 13 items. The SKAMP -Deportment (SKAMP -D) score is a measure of behavior and 
comprises of 4 items. The SKAMP -Attention (SKAMP -A) score is a meas ure of attention 
and comprises 4 items. The Higher SKAMP scores signify greater impairment. The 
SKAMP -C score will be used in the primary efficacy endpoint.  
• Permanent Product Measure of Performance (PERMP) : Rating scale will be performed 
at Visit 4, Visit 5, and Visit 6.  A Placement PERMP will be performed at Visit 2 (Day 0) to 
assure that subjects can complete at least the basic level of math problems and to determine 
the appropriate level of math to be assigned during the practice laboratory classroom day  at 
Visit 4. Based on the practice laboratory classroom day at Visit [ADDRESS_1247619] will be determined for use in the remainder of the study (Visits 5 and 6).  
The PERMP is an individual ly calibrated  five-page mathematics worksh eet consisting of 
400 problems. Subjects will be instructed by [CONTACT_891185] 10 minutes. Performance will be evaluated using two scores: 
The number of problems attempted (PERMP -A) and the num ber of problems correct 
(PERMP -C). 
14.4. Columbia -Suicide Severity Rating Scale (C -SSRS)  
Suicidal ideation will be assessed by  [CONTACT_48649] -Suicide Severity Rating Scale (C -SSRS, 
Pediatric Version)  (Posner  et al.  2010) . The “Children’s Baseline/Screening” versio n will be 
assessed at Screening, and the “Children’s Since Last Visit” version will be assessed at all visits of 
the Dose Optimization Phase (Vi sits 2, 3, 4 and 5), at Visit 6, and at Follow -Up or Early 
Termination . 
Subjects with a history of attempted sui cide or clinically significant suicidal ideation based on the 
C-SSRS assessment, in the opi[INVESTIGATOR_689], at Screening or before the last dose of study 
drug, will be excluded from further participation in the study, and further evaluation and/or  
preventive intervention steps for suicidal behavior will be taken, at the discretion of the Investigator.  
14.5. Vital Signs  
Vital sign measurements will be obtained after the subject has been seated for 3 minutes. Vital signs 
will include sitting blood pressure (systolic and diastolic measurements), pulse  rate (beats per 
minute), respi[INVESTIGATOR_697] (breaths per minute), and oral temperature . Vital signs will be collected 
once at each visit. On the full laboratory clas sroom day (Day 28  ±3 days , Visit 6), vital signs will 
Protocol KP415.E01 Amendment #[ADDRESS_1247620] has been in a supi[INVESTIGATOR_19636] a minimum of 3 
minutes.  Abnormal ECGs may be repeated  for confirmation in which case only the repeated ECG 
will be recorded.  The QT interval  corrected for heart  rate will be calculated with Fridericia’s 
formula (QTcF).  ECGs will be obtained at Screening, and at Early Termination  or Follow -Up. ECG 
recordings will be evaluated by [CONTACT_728310] a centralized ECG laboratory. One 
reader should read all the ECG recordings from a given subject.  
14.7. Clinical Laboratory Measurements  
All clinical laboratory samples will be sent to a central laboratory for analysis.  Up to approximately  
[ADDRESS_1247621] (if 
applicable) from  each subject during the study. Clinical Laboratory Measurements will be 
performed d uring the Screening Period  and at Follow -Up or Early Termination . Clinical Laboratory 
Measurements may be repeated at the discretion of the Investigator . 
The Clinical Laboratory evaluations will consist of the following:  
• Total Hematology as well as differential and Coagulation: red blood cell count, white 
blood cell count with differential (neutrophils, lymphocytes, monocytes, eosinophils, 
basophils), hemoglob in, hematocrit and platelets,  Prothrombin Time (PT) and Partial 
Thromboplastin Time (PTT).  
• Serum Chemistry: aspartate aminotra nsferase  (AST), alanine aminotransferase  (ALT), 
albumin, alkaline phosphatase, bicarbonate, total bilirubin, blood urea nitrogen, 
phosphorus (inorganic) calcium, chloride, creatine phosphokinase, creatinine, gamma 
glutamyl transferase, glucose, lactate deh ydrogenase, potassium, sodium, total protein, 
thyroid stimulating hormone (TSH), and uric acid.  TSH will be measured at Screening 
only (to evaluate the exclusion criterion for subjects with uncontrolled thyroid disease) . 
• Urinalysis: microanalysis for speci fic gravity, pH, protein, glucose, ketones, blood, 
nitrites, leukocytes. If positive  for blood, protein or nitrites , a microscopic examination 
will be performed.  
• Urine Screen for Alcohol Drugs of Abuse:  At Screening (Visit 1) and Day 0 (Visit 2), 
urine samples will be tested for alcohol  and drugs of abuse (amphetamines, 
methamphetamines, benzodiazepi[INVESTIGATOR_1651], barbiturates, cannabinoids, cocaine, opi[INVESTIGATOR_728283]) . If the urine test is positive for alcohol  and drugs of abuse  at 
Screening, the subjec t will be excluded from study participation, with the exception of the 
following: Depending on a subject's current ADHD medication at Screening, the urine 
Protocol KP415.E01 Amendment #[ADDRESS_1247622] washed out  
their ADHD medications before  Visit 2  
• Urine Screen for Methylphenidate: At Screening (Visit 1), on  Day 0 (Visit 2), and at Visit 
5, before administration of study drug,  urine samples will be tested for methylphenidate . 
A urine dipstick (e.g., NarcoCheck®) will be used to screen for the presence of 
methylphenidate in the urine . If a subject's current AD HD medication at Screening 
contains MPH, the urine screen at Screening may test positive for MPH. Since all ADHD 
medications must be washed out by [CONTACT_2006] 0, they must test negative on Day 0 (Visit 2) for 
subjects to be eligible to continue in the study.  The M PH urine screen at Visit [ADDRESS_1247623]  
Pregnancy Tests: will be performed for all female subjects of childbearing potential. A  serum β -
hCG pregnancy test will be performed at Screening. A urine pregnancy test will be performed at 
Visit 2 (Day 0), Visit 5 (Day 21), and at Follow -Up or Early Termination. A positive pregnancy test 
before the last dose of study drug will exclude  a subject from further participation in the study. A 
positive urine pregnancy test will be confirmed with a serum β -hCG pregnancy test.  
Childbearing potential is defined as follows: Girls under the age of [ADDRESS_1247624] 
period will be consider ed “not of child -bearing potential”. Girls of 12 years and older (including 
girls who will become 12 years or older during the study) will be considered “of child -bearing 
potential”, even if they have not yet had their first period. Irrespective of age, gi rls who have had 
their first period, will be considered “of child -bearing potential”.  
14.9. Adverse Event Assessments  
Adverse Events will be assessed and recorded from Day 1 through either Follow -Up or Early 
Termination. While subjects are in the laboratory classroom  after administration of study drug  (Visit 
6), AEs will be monitored continuously  by [CONTACT_464] . During administration of study drug away 
from the research clinic, s ubject’s parent/guardian will be instructed to contact [CONTACT_891186] . In addition, study staff will inquire 
parent/guardian during the next study visit about AEs during the dosing period at home . Definitions 
and details of AE rep orting and documentation are listed in Section  18. 
Protocol KP415.E01 Amendment #[ADDRESS_1247625]’s best interest to continue. The 
following is a list of possible reasons for study treatment discontinuation:  
• Subject withdrawal of consent . 
• Subject is not compliant with study procedures.  
• Adverse event that in the opi[INVESTIGATOR_891165] . 
• Protocol violation requiring discontinuation of study treatment . 
• Lost to follow -up. 
• Sponsor request for early termination of the study . 
• Positive pregnancy test ( tested in females  of childbearing  potential ). 
• Out-of-range v ital signs , at the discretion of the Investigator. I n order to ensure accuracy, 
out-of-range vital signs may be repeated once, at least 2 minutes  after an abnormal 
finding.  
• For other reasons (e.g., significant protocol violation,  non-compliance, overdose).  
 
If a subject is withdrawn from treatment due to an adverse event, the subject will be followed and 
treated by [CONTACT_41848].  
All subjects are free to withdraw from participation at any time, for any reason, specified or 
unspecified, and without prejudice.  
If a subject  meets withdrawal criteria during the Open -Label Dose  Optimization Phase or the 
Double -Blind Treatment Phase , the subject will be withdrawn  and Early Termination procedures 
will be completed . 
At the discretion of the Investigator, ensuring the safety of the subjects, any ET procedures that 
were already performed on the same day as part of the procedures of the Open -Label Dose  
Optimiz ation Phase or the Double -Blind Treatment Phase  do not need to be repeated.  
15.2. Replacement of Subjects  
Subje cts who withdraw from the study during the Double -Blind Treatment Phase will not be 
replaced.  Subjects who withdraw from the study during the Open -Label Dose  Optimization Phase 
may be replaced . 
16. EFFICACY ENDPOINTS  
The following endpoints will be used to determine efficacy:  
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 65 of 81  April 6, 2018  
 16.1. Primary Efficacy Variable : 
• Average of the change from baseline (measured at Visit 5) of the SKAMP -C scores collected 
across the laboratory classroom day a t Visit 6.  
16.2. Secondary Efficacy Variables :  
• Change from baseline (measured at Visit 5) of the  SKAMP -C scores measured at each time 
point on the  laboratory classroom day  at Visit [ADDRESS_1247626] of KP415.  
• Change from baseline of the s cores measured at each time point and the average of the 
scores collected across  the laboratory classroom day at Visit 6 , for the following endpoints : 
o SKAMP -D and SKAMP -A scores  
o PERMP scores  
o PERMP -A and PERMP -C scores  
• WREMB -R scores (total score, and morning and evening subscore) at Baseline  (Visit 2) , 
Visit 5 and Visit 6 . 
16.3. Safety Endpoints:  
The occurrence of Treatment -Emergent Adverse Events (TEAEs) will  be assessed starting 
following the first dose of open -label drug (KP415), and ending with the Follow -Up Visit or Early 
Termination Visit. Additional safety evaluations will include physical examination s, vital signs, as 
well as height and weight, ECG Para meters, clinical  laboratory tests, and a follow -up C -SSRS 
administered at each study visit.  AEs during the Open-Label Dose  Optimization Phase and the 
Double -Blind Treatment Phase will be will be reported and analyzed separately . 
17. STATISTICAL CONSIDERATIONS  
This section summarizes the statistical considerations for this protocol. Details will be provided in 
the Statistical Analysis Plan for Protocol No: KP415.E01 (SAP_KP) prior to the primary endpoint 
database lock and unblinding of the trial.  
17.1. Statistical Hyp otheses  
17.1.1.  Primary Efficacy Endpoint(s):  
The primary efficacy endpoint will be the mean change from the baseline measurement at Visit 5  
and SKAMP -C scores ( ∆𝑆𝐾𝐴𝑀𝑃−𝐶 ̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅) collected across the labo ratory classroom day at Visit 6.  
Protocol KP415.E01 Amendment #[ADDRESS_1247627] of the secondary endpoints:  
 
• ∆𝑆𝐾𝐴𝑀𝑃−𝐶 ̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅ scores at each time point on the  laboratory classroom day  at Visit [ADDRESS_1247628]-dosing will be used to determine onset and duration 
of the clinical effec t of KP415.  
• The mean change  from baseline  at each time point collected across the laboratory classroom 
day at Visit 6 for the following endpoints : 
o SKAMP -D and SKAMP -A scores  
o PERMP scores  
o PERMP -A and PERMP -C scores  
• WREMB -R scores (total score, and morning and evening subscore)  
 
17.2. Sample Size Calculation  
Test Treatment does not have Carry -over Effect:  The primary hypothesis is that the test drug is 
superior (change  in SKAMP -C from baseline measured at V isit 5 are lower ) when compared to 
placebo.  The null and alternative hypotheses are as follows : 
 
𝐻0:∆𝑆𝐾𝐴𝑀𝑃−𝐶 ̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅𝑐𝑜𝑛𝑡𝑟𝑜𝑙−∆𝑆𝐾𝐴𝑀𝑃−𝐶 ̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅𝑡𝑒𝑠𝑡=0 
𝐻𝐴:∆𝑆𝐾𝐴𝑀𝑃−𝐶 ̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅𝑐𝑜𝑛𝑡𝑟𝑜𝑙−∆𝑆𝐾𝐴𝑀𝑃−𝐶 ̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅̅𝑡𝑒𝑠𝑡≠[ADDRESS_1247629] a clinically and statistically relevant (p <0.05) interaction effect 
between treatment and time.  Therefore, if the interaction between treatment and time is statistically 
relevant, then the hypothesis test will be based on the interaction effect.  If the interaction is not 
statistically relevant, then the hypothesis test will be based on just the treatment main effect.  
Drug efficacy studies are sized to be able to detect at least the Minimum Clinically Important 
Difference (MCID). MCID has not been established for the SKAMP -C scores. However, Rai  et al.  
(Rai et. al.  2015)  noted “0.[ADDRESS_1247630] deviations has been suggested to correspond to the MCID in 
a number of studies“. Biederman et al. (Biederman et al. 2007) also noted, in a similar study on 
lisdexamfetamine dimesylate, “Previous studies of amphetamine products using the SKAMP -D to 
assess efficacy in children with ADHD have disclosed an effect size of greater than .50.”  Therefore, 
the SD is assumed to be 1 and the MCID is assumed to be 0.5.  
Protocol KP415.E01 Amendment #[ADDRESS_1247631] and control for SKAMP -C of 0.[ADDRESS_1247632] deviation (SD) of 1.0, 126 subjects would need to complete the study, assuming 80% 
power when testing a significance level of  = 0.05 ([ADDRESS_1247633]). Figure [ADDRESS_1247634] size with a range and SD’s.  The figure shows that even if the SD is 
50% greater than expected, the minimum detectable effect size changes from -0.5 to -.0.7. Given 
previous studies of amphetamine products using ∆𝑆𝐾𝐴𝑀𝑃−𝐶 in a classroom setting showed 
differences of greater than 1 with SD’s close to 1 (McCracken et al. 2003 ; Biederman  et al. 2007 ; 
Swanson et al. 1998 ). 
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 68 of 81  April 6, 2018  
 Figure 2: Change in Effect Sizes for a Range of Standard Deviations  
  
The samples sizes are based on the Two Sample Z -Test assuming Equal Variance module in PASS 
Version 15.0.3.  
Assuming an approximate 10% dropout during the Double -Blind Treatment Phase, 140 subjects are 
planned to be randomized in the Double -Blind Treatment  Phase. Assuming an approximate  20% 
dropout during the Open -Label Dose Optimization Phase, 176 subjects are planned to be enrolled 
in the Open -Label Dose Optimization Phase.  

Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 69 of 81  April 6, 2018  
 17.3. Populations for Analysis  
There are three populations in this study:  
Intent -to-Treat (ITT) Population: All randomi zed subjects who receive at least one dose of 
double -blind study medication and have at least one post-dose SKAMP -C assessments  at Visit 
6. 
Per-Protocol (PP) Population: ITT subjects who received the morning dose of double -blind 
study medication at the lab oratory test session, who have all [ADDRESS_1247635]-dose SKAMP -C assessments  
at Visit 6 , who did not miss more than 2 days of therapy during the Double -Blind Treatment 
Phase, and did not use prohibited medications during the Double -Blind Treatment Period.  
Overall Sa fety Population:  All subjects who entered the Open -Label Dose Optimization phase 
and received at least one dose of open -label study medication and had at least one post -dose 
safety assessment . This will include subjects who were randomized as well as those  subjects 
who were never randomized. This population will be used for safety analyses.  
17.4. Statistical Analyses  
17.4.1.  General Approach  
Analysis Populations : All baseline analys es will be performed using the ITT, PP and Overall Safety  
populations.  All efficacy analys es will be performed using both the ITT and PP populations.  All 
safety analyses will use the Overall Safety Population . 
Descriptive Statistics:  For descriptive statistics, the following will be reported:  
• Continuous data: n, mean, standard deviation, median  and interquartile range, minimum 
and maximum  
• Categorical: n/N, percentage of total per arm and 95% confidence interval per category  
• Binary: n/N, percentage per arm and 95% confidence interval  
 
Missing Data:  The following applies to the primary and seconda ry efficacy endpoint and safety 
analyses.  If there is < 5% of patients with outcome data points missing, then no additional sensitivity 
analyses will be performed.  If there are ≥ 5% of patients with missing outcome data, then the 
missingness will be assess ed. If the outcome data is considered to missing at random (MAR), no 
additional steps will be taken to handle the missing data (see SAP for details).  If the outcome data 
is Not Missing at Random (NMAR), a sensitivity analysis using  a pattern -mixture model  (see SAP 
for details) will be performed.  
If there is < 5% of patients with covariate data values missing, then no additional sensitivity analyses 
will be performed.  If there are  5% of patients with missing covariate data values, then the 
missingness will be assessed.  If the covariate data is considered to be MAR , a sensitivity analyses 
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 70 of 81  April 6, 2018  
 using multiple imputation methods (see SAP for details) will be performed.  If the covariate  data is 
NMAR, alternative imputation methods such as pattern mixture model will be assessed (see SAP 
for details).  
Any change to the data analysis methods described in the protocol will require an amendment only 
if it changes a principal feature of the protoc ol. Before unblinding of the aggregate database, minor 
modifications or clarifications to the data analysis methods may be described and justified in the 
statistical analysis plan. Any retrospective or exploratory analyses not defined by [CONTACT_891187].  
17.4.2.  Analysis of t he Primary Efficacy Endpoint  
The primary efficacy endpoint treatment effect is the SKAMP -C scores over the day during Visit 
6. Though the SKAMP questionnaire uses the Likert scale, the SKAMP -C, which aggregates the 
scores from all the domains, will be treated as a continuous measure.  
The estimate of the difference between test and control will be based on a repeated measures 
analysis using a Mixed -Effect Model Repeated Measure (MMRM) model where:  
• Time, treatment and the interaction of time and treatment are the fixed effects . Site will be 
included as a fixed effect. If site effect is not statistically significant, it will be removed 
from the model . 
• Subject is the random effect . 
 
Prior to conducting any analyses, we will be looking at the distribution of data. The outcome data 
will be assessed for normality using Shapi[INVESTIGATOR_2152] -Wilk (SW) test.  If there is evidence of a lack of 
normality, several normalizing transformations will b e considered.  See SAP for details.  Point 
estimates for each treatment group and treatment mean group differences (KP415 – Placebo) will 
be presented  with standard errors and 95% confidence intervals  An unstructured (co)variance 
structure shared across trea tment groups will be specified to model the within -subject errors . If the 
p-value for interaction between treatment and baseline covariate is not < 0.05, then that covariate 
will be dropped from the model and the analysis will be re -run. Model fit will be assessed using 
graphical and quantitative methods.  See SAP for details.  
Studies of this type often have a clinically and statistically relevant (p <0.05) interaction effect 
between treatment and time. Therefore, if the interaction between treatment and tim e are statistically 
relevant, then the hypothesis test will be based on the interaction effect. If the interaction is not 
statistically relevant, then the hypothesis test will be based on just the treatment main effect.  
17.4.3.  Analysis of t he Secondary Endpoint s 
The secondary endpoint analyses described in this section will be performed if the primary endpoint 
Protocol KP415.E01 Amendment #[ADDRESS_1247636] is not significant, only the 
descriptive statistics will be provided.  
SKAMP -C measur ed at each time point at Visit 6:  The same MMRM model developed for the 
primary efficacy endpoint will be used to estimate the least square means and their correspo nding 
95% confidence interval for each time and treatment combination.  Differences in least square means 
between  the treatment arms and unadjusted p -values will be reported  for each time point . 
Onset of clinical effect is defined as the earliest post -dose time point at which the difference between 
KP415 and Placebo is statistically significant (p <0.05)  between KP415 and placebo as measured 
by [CONTACT_891188] -C Score . The duration of the treatment effect is defined as the length of the time 
interval, such that statistical significance was reached at each time point of this interval . 
All other secondary endpoints : The remaining secondary endpoints will be treated as continuous 
data.  The overall interaction effect of treatment and time or the treatment effect i f the interaction is 
significant and the individual time point estimates will be determined using  the same model analysis 
methods and output described for the SKAMP -C endpoint.  
17.4.4.  Sensiti vity Analyses  
As a sensitivity analysis, the interaction of treatment and unbalanced baseline covariates identified 
in the baseline characteristic analysis will be inclu ded in the primary and secondary models. If the 
p-value for interaction between treatment and baseline covariate is not significant (p  ≥0.01), then 
that covariate will be dropped from the model and the analysis will be re -run. 
17.4.5.  Safety Analysis  
All analyses of safety will be conducted on the Overall Safety Population.  The safety assessment 
will be based on adverse events, physical exams, vital signs, ECG parameters , clinical laboratory 
tests and C -SSRS scores . 
Adverse events will be coded in accordance with t he Medical Dictionary for Regulatory Activities 
(MedDRA). Adverse events with new onset during the study between the initiation of study drug 
and [ADDRESS_1247637] dose of study drug will be considered treatment -emergent (TEAEs). This 
will include any AE with onset prior to initiation of study drug and increased severity after the 
treatment initiation.  
TEAEs  will be summarized by [CONTACT_6657], and by [CONTACT_3148]. This will 
include overall incidence rates (regardless of severity and relationship to study drug) and incidence 
rates for moderate or severe adverse events. A summary of seriou s adverse events and adverse 
events leading to early discontinuation from the study will be summarized by [CONTACT_3148].  
Safety laboratory tests and vital signs will be summarized by [CONTACT_447] -treatment change from baseline 
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 72 of 81  April 6, 2018  
 for each of the parameters using descript ive statistics by [CONTACT_1570]. Those subjects with 
significant laboratory abnormalities will be identified in data listings. Additional safety parameters 
will be summarized in data listings.  See Section 18  for more information on safety data.  
17.4.6.  Baseline Descriptive Statistics  
The key baseline characteristics (see the Statistical Analysis Plan (SAP) for list of baseline 
characteristics) will summarized descriptively per treatment  arm and the two arms will be compared 
statistically.  For continuous variables , the data will be assessed as to whether they are normally 
distributed using the Shapi[INVESTIGATOR_2152] -Wilk test (SW).  If this is no evidence of lack of normality (SW 
p>0.05), then the two arms will be compared using the t -test with unequal variances.  If SW indicates 
that there is evidence that the variable is not normally distributed (SW p < 0.05), then the non -
parametric Wilcoxon rank sum test will be used to compare the two arms. For binary and categorical 
variables, the chi -square test will be used for the comparis on between the two arms.   
As a sensitivity analysis,  if there is evidence of a difference in baseline characteristics (p <0.01), 
and the difference is considered clinically relevant by [CONTACT_079]  [INVESTIGATOR_7966], the 
primary and secondary effi cacy endpoint analyses will include these variables as covariates.  
17.4.7.  Planned Interim Analyses  
There are no planned interim analyses . 
17.4.8.  Sub-Group Analyses  
The subgroup analyses described in this section will be performed if the primary endpoint is 
significant.  If the primary endpoint is not significant, then only the descriptive statistics will be 
provided.  
The primary efficacy endpoint model and analysis methods along with the safety endpoints and 
analyses will be used to analyze any subgroups such as site, do se, age and gender.  Please see the 
SAP for the list of subgroup and further details about the analyses.  
17.4.9.  Tabulation of Individual Participant Data  
A listing of date and type of each subject ’s TEAE  will be provided.  
17.4.10.  Exploratory Analyses  
Changes in ADHD sever ity will be compared  from week to week in the ITT and PP Population 
based on ADHD -RS-5, CGI -S, CGI -I, and Conners 3 -P. Please see the SAP for further details about 
the analyses.  
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 73 of 81  April 6, 2018  
 18. ADVERSE EXPERIENCE REPORTING AND DOCUMENTATIO N 
18.1. Adverse Events  
18.1.1.  Recording and Mo nitoring of Adverse Events  
For the purpose of this clinical trial, all Adverse Events will be recorded and monitored for all 
enrolled subjects from the moment they receive the  dose of study drug  until they complete the study 
at the EOS (the Follow -Up visit  or the Early Termination Visit) . 
18.1.2.  Definition  
An adverse event (AE) is any untoward medical occurrence in a clinical investigation of a patient 
administered a pharmaceutical product and that does not necessarily have a causal relationship with 
the treatment . An AE is therefore any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom or disease temporally associated with the administration of an 
investigational product, whether or not related to that investigational product. An unexpected AE is 
one of a type not identified in nature, severity, or frequency in the current Investigator’s Brochure 
or of greater severity or frequency than expected based on the information in the Investigator’s 
Brochure.  
The Investigator will probe, v ia discussion with the subject, for the occurrence of AEs during each 
subject visit and record the information in the site’s source documents. Adverse events will be 
recorded in the patient eCRF. Adverse events will be described by [CONTACT_24109] (start and stop  dates and 
times), severity, outcome, treatment and relation to study drug, or if unrelated, the cause.  
18.1.3.  AE Grading   
Adverse Events shall be graded with regard to severity according to criteria defined in the Common 
Terminology Criteria fo r Adverse Events v 4.0 (CTCAE). Grade refers to the severity of the AE. 
The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE 
based on this general guideline.  
Grade 1  Mild ; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated.  
Grade 2  Moderate; minimal, local or noninvasive intervention indicated; limiting age -
appropriate instrumental Activity of Daily Living (ADL) . 
Grade 3  Severe or medically significant but not immediately life -threatening; 
hospi[INVESTIGATOR_3111]; disabling; limiting 
self-care ADL.  
Grade 4  Life-threatening consequences; urgent intervention indicated.  
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 74 of 81  April 6, 2018  
 Grade 5  Death related to AE.  
18.1.4.  AE Relationship to Study Drug  
The relationship of  an AE to the study drug should be assessed using the following : 
1. Definitely - Previously known toxicity of agent; or an event that follows a reasonable 
temporal sequence from administration of the drug; that follows a known or expected 
response pattern to the suspected drug; that is confirmed by [CONTACT_13635][INVESTIGATOR_528026]; and that is not explained by [CONTACT_41846].  
2. Probably - An event that follows a reasonable temporal sequence from administration of the 
drug; that follow s a known or expected response pattern to the suspected drug; that is 
confirmed by [CONTACT_13635][INVESTIGATOR_11125]; and that is unlikely to be 
explained by [CONTACT_20612]’s clinical state or by [CONTACT_41847].  
3. Possibly - An event that follows a reasonable temporal sequence from administration of the 
drug; that follows a known or expected response pattern to that suspected drug; but that 
could readily have been produced by a number of other factors.  
4. Unrelated - An e vent that can be determined with certainty to have no relationship to the 
study drug.  
18.2. Serious Adverse Events 
A Serious Adverse Event ( SAE ) is defined as any AE occurring at any dose that results in any of 
the following  outcomes:  
• Death 
• A life-threatening adverse experience  
• Inpatient hospi[INVESTIGATOR_1081]  
• A persistent or significant disability/incapacity  
• A congenital anomaly/birth defect  
• Other important medical events may also be considered an SAE when , based on 
appropriate medical judgment, they jeopardize the subject or require intervention 
to prevent one of the outcomes listed.  
 
Note that AEs of Grade 3 due to hospi[INVESTIGATOR_17127] a hospi[INVESTIGATOR_059], and Grade 4 
and Grade 5 per CTCAE gra ding criteria are classified as SAEs.  
18.2.1.  Serious Adverse Event Reporting  
Within 24 hours after a SAE detection, observation, or report of occurrence (regardless of the 
Protocol KP415.E01 Amendment #[ADDRESS_1247638] article) , the Investigator or designee will enter the SAE into the electronic 
database. The investigator/qualified designee will enter the required information regarding the SAE 
into the appropriate module of the eCRF, which will automatically result in distribution of the 
information to the appropriate spons or contact. If the EDC system is temporarily unavailable, the 
event, including the investigator -determined causality to study drug, should be reported via a paper 
back-up SAE form to the appropriate sponsor contact. Upon return of the availability of EDC 
system, the SAE information must be entered into the eCRF.  
If EDC is not functional, a paper SAE form will be utilized and provided to the following contact : 
[CONTACT_891189] [EMAIL_16966]  
Fax: 919 -668-7138  
Telephone: [ADDRESS_1247639] contain the following information:  
1. Study name/number  
2. Study Drug  
3. Investigator details (name, phone, fax, e -mail)  
4. Subject Number  
5. Subject Demographics  
6. Clinical Event  
7. Description  
a. Date of onset  
b. Treatment (drug, dose, dosage form)  
c. AE Relationship to study drug  
d. Action taken regarding study drug in direct relationship to the 
AE 
e. Criteria for “Serious” applicable to the AE  
8. Cause of death (whether or not the death was related to study dru g) 
9. Autopsy findings (if available)  
 
Any SAE that occurs during the study  should be recorded by [CONTACT_728315], and reported to the 
ARO. T he ARO will notify  the Sponsor  by [CONTACT_891190] . 
SAEs considered definitely, probably, or possibly related to study drug shall also be classified by 
[CONTACT_728316] “expected” or “unexpected.” An unexpected event is one that is not listed in the 
investigator’s brochure (KP415) . 
The person responsible fo r the study shall ensure the study has been carried out in accordance with 
local pharmacovigilance regulations.  
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 76 of 81  April 6, 2018  
 All serious event reporting by [CONTACT_355795] 21 CFR 312.32 for IND drugs (7-day or 15 -
day alerts) and 21 CFR 314.80 for marketed drugs (15-day alerts). Unexpected fatal or life -
threatening SAEs considered related to the study drug should be reported to the FDA by [CONTACT_891191] D Safety report within [ADDRESS_1247640] (IRB) will be notified of 
the alert reports per  FDA regulations.  
18.3. Adverse Event Treatment and Follow -Up 
All AEs, including SAEs, will be followed to resolution when possible. All AEs and treatment 
administered will be recorded on the electronic C ase Report Form ( eCRF).  Treatment may be 
rendered on site under the direction of th e Investigator as appropriate. Events requiring diagnostic 
evaluation or treatment beyond the scope of what is available and appropriate within the clinical 
research unit shall be referred in a timely basis to other care providers.  Records of diagnostic and 
therapeutic interventions shall be requested in compliance with HIPAA requirements, and those 
received shall be retained in the subject’s file.  
For SAEs that occur during the study, the assessment, treatment, and follow up shall be performed 
for up to at least [ADDRESS_1247641] dose  used in the study, i.e., 
>40 mg KP415. Notifications of known incidences  of subjects taking more than one capsule of 
study drug per day (irrespect ive of the dose size) will be provided by [CONTACT_891192]. 
The ARO will notify the sponsor before the end of the next business day  after ARO’s notification 
receipt from the site . If there is an associated AE or SAE, the site is to report the eve nt on the 
electronic case report form within 24  hours. 
Known signs and symptoms  after acute overdosage  of d -MPH, resulting principally from 
overstimulation of the central nervous system and from excessive sympathomimetic effects, include 
vomiting, agitatio n, tremors, hyperreflexia, muscle twitching, convulsions (may be followed by 
[CONTACT_355797]), euphoria, confusion, hallucinations, delirium, sweating, flushing, headache, hyperpyrexia, 
tachycardia, palpi[INVESTIGATOR_814], cardiac arrhythmias, hypertension, mydriasis, and dryn ess of mucous 
membranes  (Concerta® Extended Release Package Insert 2008, Focalin® Package Insert 2017, 
Focalin® XR Package Insert 2015, Ritalin® and Ritalin -SR® Package Insert 2015 ). Rhabdomyolysis 
has also been reported (Ritalin® and Ritalin -SR® Package Insert 2015 ). 
19. PREGNANCY  
Females with a positive pregnancy test will terminate the study early. The initial report of a 
pregnancy  during the study will be provided  by [CONTACT_891193]. The ARO will notify the 
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 77 of 81  April 6, 2018  
 Sponsor before the end of the next b usiness day  after ARO’s notification by [CONTACT_779],  and ARO will 
report to the IRB within a time frame  after the incident identification  as required by [CONTACT_36985].  
All pregnancies will be followed to at least the completion/termination of the pregnancy. The 
Investigator will document the subject visit s accordingly  and record the information in the clinical 
site’s source documents. If the pregnancy continues to delivery , the outcome (health of the infant), 
in addition to the maternal health status, must be includ ed in the report.  
Pregnancy will not be considered an AE or SAE ; any pregnancy complication or termination of a 
pregnancy for medical reasons will be recorded as an AE or SAE.  
20. PROTOCOL VIOLATIONS  
A protocol violation occurs when the subject, Investigator, or Sponsor fails to adhere to significant 
protocol requirements that materially (a) reduces the quality or completeness of the data, (b) makes 
the Informed Consent Form inaccurate, or (c) impacts a subject's safety, rights, or welfare. 
Examples of protocol  violations may include the following:  
1. Inadequate or delinquent Informed Consent  
2. Inclusion/exclusion criteria not met  
3. Unreported serious adverse events  
4. Improper breaking of the blind  
5. Multiple visits missed or outside permissible windows  
6. Materially inadequate record keepi[INVESTIGATOR_007]  
7. Intentional deviation from protocol, Good Clinical Practice, or regulations by [CONTACT_25617]  
8. Subject repeated non -compliance with study requirements  
 
It is the Site Investigator’s responsibility to report to the IRB any Protocol  Violation(s) according 
to the IRB ’s policy. A copy of the IRB submission will be filed in the site’s regulatory binder and 
in the Sponsor’s files  at the ARO . 
21. DATA MANAGEMENT AND RECORD KEEPI[INVESTIGATOR_1645]  
21.1. Data Management  
Data will be recorded at the site on eCRFs. Al l entries on a eCRF are ultimately the responsibility 
of the Site Investigator, who is expected to review each form for completeness, accuracy and 
legibility before signing. All forms must be filled out by [CONTACT_728320]. Errors should be lined out 
but no t obliterated and the correction inserted, initialed and dated. A n eCRF must be completed for 
each participant for whom parental permission was obtained and who has given written  or verbal  
assent.  The eCRFs and source documents must be made available to the Sponsor and/or its 
representatives.  
Protocol KP415.E01 Amendment #[ADDRESS_1247642] Keepi[INVESTIGATOR_524999] s and Academic Research Organization  (ARO)  must maintain all documents 
and records, originals or certified copi[INVESTIGATOR_63062], relating to the conduct of this trial, and 
necessary for the evaluation and reconstruction of the clinical trial. This documentation includes, 
but is not limited to , protocol, eCRFs, AE reports, subject source data (including records of subjects, 
subject visit logs, clinical observations and findings),  correspondence with health authorities and 
IRB, consent forms, inventory of study product, Investigator’s curriculum vitae, and monitor visit 
logs.  
The Site Investigator s, their  affiliated Institution s and the ARO should maintain the trial documents 
as required by [CONTACT_1729] , and should take measures to prevent accidental or 
premature destruction of documents. Clinical trial documents must be kept in the clinical site’s and 
ARO’s archives until written authorization is obtained from the Sp onsor.  
21.3. Access to Source Data/Documents  
The Site Investigator s and ARO  agree that the Sponsor, their representatives, the IRB, and 
representatives from worldwide regulatory agencies will have the right, both during and after the 
clinical trial, to review an d inspect pertinent medical records related to the clinical trial.  
22. QUALITY CONTROL AND QUALITY ASSURANCE  
Sponsor and/or Sponsor’s representatives will perform quality control and quality assurance checks 
of this clinical trial that it sponsors. Before the enrollment of any patient in this study, personnel of 
the ARO will review with the Site Investigators and site personnel the appropriate documents and 
processes to conduct the trial including the protocol, Investigator’s Brochure, eCRFs and 
procedures for their completion, the informed consent process, and the procedure for reporting 
SAEs. Site visits will be performed by [CONTACT_891194], or—as needed --other ARO personnel 
and/or other Sponsor personnel and/or representatives. During these visits, information recorded on 
the eCRFs will be verified against source documents and requests for clarification or correction 
may be made. After the eCRF data is entered by [CONTACT_779], ARO personnel will review for safety 
information, completeness, accuracy, and logical consistency. Computer programs that identify data 
inconsistencies may be used to help monitor the clinical trial. If necessary, requests for clarification 
or correction will be sent to Site Investigators.  
The ARO and Sponsor agree to be responsible  for implementing and maintaining quality control 
and quality assurance systems with written standard operating procedures to ensure that the clinical 
trial is conducted and data are generated, documented, and reported in compliance with the protocol 
and a ccepted standards of Good Clinical Practice (GCP)  per the International Council for 
Harmonisation (ICH E6(R2)) . 
Protocol KP415.E01 Amendment #[ADDRESS_1247643] their origin in  the Declaration of Helsinki, and 
that the clinical trial data are credible. In this study, the 2008 version of the Declaration of Helsinki 
will be adhered to. It can be found on the website of The World Medical  Association: 
http://www.wma.net/en/30publications/10policies/b3/17c.pdf  
24. INSURANCE  
24.1. Insurance Compensation  
The Sponsor certifies that it has taken out a liability insurance policy covering all clinical trials 
under its sponsor ship. This insurance policy is in accordance with local laws and requirements. The 
insurance of the Sponsor does not relieve the Site Investigator s and the other collaborators from 
maintaining their own liability insurance policy. An insurance certificate will be provided to the 
IRB according to regulatory requirements.  
25. COMPLETION OF STUDY  
The end of the study will be at the time of the last subject, last visit. The IRB will be notified about 
the end of the study according to regulatory requirements.  
26. STUDY ADMINISTRATIVE INFORMATION  
26.1. Protocol Amendments  
Any amendments to the study protocol considered to be a substantial amendment will be 
communicated to the Site Investigator s by [CONTACT_688950] . All substantial protocol amendments will 
undergo the same review and app roval process as the original protocol and may be implemented 
after it has been approved by [CONTACT_1201], unless immediate implementation of the change is necessary 
for subject safety. In this case, the situation must be documented and reported to the IRB accor ding 
to all relevant regulatory requirements.  
A protocol amendment is considered to be a substantial amendment if it is likely to affect the safety, 
physical, or mental integrity of subjects in the study; the scientific value of the study; the conduct 
or management of the study; or the quality or safety of any Investigational Medicinal Product used 
in the study.  
Any other minor changes to the protocol not considered to be substantial amendments will not need 
prior approval of the IRB and will be communicate d to the Site Investigator s by [CONTACT_688950] . 
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 80 of 81  April 6, 2018  
 27. REFERENCES  
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth  
Edition (DSM -5). Arlington , VA, American Psychiatric Association , 2013. 
Biederman J, Boellner SW, Childress A,  Lopez FA, Krishnan S, Zhang Y. Lisdexamfetamine 
dimesylate and mixed amphetamine salts extended -release in children with ADHD: a double -
blind, placebo -controlled, crossover analog classroom study. Biol Psychiatry. 2007;62(9):970 -6. 
Busner J, Targum SD. Th e Clinical Glo bal Impressions Scale: Applying a research tool in 
clinical practice. Psychiatry 4:28 –37, 2007.  
Carlson GA , Dunn D, Kelsey D, Ruff D, Ball S, Ahrbecker L, Allen AJ.  A pi[INVESTIGATOR_891166]: safety of conc omitant therapy in children with 
attention -deficit/hyperactivity disorder  (2007). Child Adolesc Psychiatry Ment Health. 1(1):10.  
Challman TD , Lipsky JJ.  Methylpheni date: its pharmacology and uses (2000). Mayo Clin Proc. 
75(7):711 -21. 
Concerta® Extended Rel ease [Package I nsert]. Janssen Pharmaceuticals, Inc. 20 08. 
DuPaul GJ, Power TJ, Anastopoulos AD, Reid R: ADHD Rating Scale -5 for Children and 
Adolescents: Checklists, Norms, and Clinical Interpretation. [LOCATION_001]: Guildford, 2016  
Focalin® [Package I nsert]. [COMPANY_001] Pharmaceuticals Corporation . 2017. 
Focalin® XR [Package I nsert]. [COMPANY_001] Pharmaceuticals Corporation . 2015. 
Lawrence V, H oughton S, Douglas G, Durkin K, Whiting K, Tannock R: Executive function and 
ADHD: A compa rison of children’s performance during  neuropsychological testing and real-
world activities . J Atten Disord 7:137 –149, 2004.  
Leonard BE , McCartan D, White J, King DJ.  Methylphenidate: a review of its 
neuropharmacological, neuropsychological and adverse clinical effects.  Hum Psychopharmac ol. 
19:151-80, 2004.  
McCracken JT, Biederman J, Greenhill LL, Swanson JM, McGough JJ, Spencer TJ, et al. Analog 
classroom assessment of a once -daily mixed amphetamine formulation, SLI381 (Adderall XR), in 
children with ADHD. Journal of Child and Adolescent  Psychiatry. 42:673 –683, 2003.  
Morton WA, Stockton GG. Methylphenidate Abuse and Psychiatric Side Effects  (2000) . Primary 
Care Companion to The Journal of Clinical Psychiatry . 2:159-164. 
Posner K, Brent D, Lucas C, Gould M, Stanley B , Brown G , Fisher P, Zelazny J, Burke A, Oquendo 
M, Mann J. Columbia -Suicide Severity Rating Scale (C -SSRS) Pediatric Baseline Version. New 
York, NY: The Research Foundation for Mental Hygiene, Inc., 2010 . 
Protocol KP415.E01 Amendment #2  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 81 of 81  April 6, 2018  
 Rai SK, Yazdany  J, Fortin  PR and Aviña -Zubieta  JA. Approaches for estimating minimal clinically 
important differences in systemic lupus erythematosus . Arthritis Research & Therapy  17:143 -, 
2015.  
Ritalin® and Ritalin -SR® [Package I nsert]. [COMPANY_001] Pharmaceuticals Corporation . 2015. 
Swanson J, Wigal S, Greenhill L, Browne R, Waslik B, Lerner M, Williams L, Flynn D, Agler 
D, Crowley K, Fineberg E, Baren M, Cantwell D. Analog classroom assessment of Adderall in 
children with ADHD. J Am Acad Child Adolesc Psychiatry. 37:519 –526, 1998.  
Swanson JM, Gupta S, Lam A, Shoulson I, Le rner M, Modi N, Lindemulder E, Wigal S. 
Development of a new once -a-day formulation of methylphenidate for the treatment of attention -
deficit/hyperactivity disorder: Proof -of-concept and proof -of-product studies. Archi ves of 
General Psychiatry. 60:204 –211, 2003 . 
Swanson JM, Agler D, Fineberg  E, Wigal S, Flynn S, Fineberg K, Quintana Y  and Talebi H , The 
University o f [LOCATION_004], Irvine , Laboratory  School Protocol for Pharmacokinetic and 
Pharmacodynamic Studies. in: L Greenhill, B Osman (Eds.) Ritalin. 2nd ed. Mary Ann Liebert, 
Larchmont, NY; 1999:405 –430. 
Swanson JM, Wigal SB, Wigal T, Sonuga -Barke E, Greenhill LL, Biederman J, Kollins S, 
Nguyen AS, DeCory HH, Hirshey -Dirksen SJ, Hatch SJ COMACS Study Group. comparison of 
once -daily extended -release methylp henidate formulations in children with attention -
deficit/hyperactivity disorder in the laboratory school (The Comacs Stud y) Pediatrics. 113:206 –
216, 2004.  
Westfall, P. H., Tobias, R. D., Rom, D., Wolfinger, R. D., and Hochberg, Y. (1999), Multiple 
Comparis ons and Multiple Tests Using the SAS System, Cary, NC: SAS Institute Inc.  
Wilens TE, Biederman J. The stimulants. Psychi atric Clinics of North America. 15:191 -222, 
1992 . 
Wilens T, Adler  LA, Adams  J, Sgambati  S, Rotrosen  J, Sawtelle  R, Utzinger  L and Fusill o S. 
Misuse and diversion of stimulants prescribed for ADHD: a syste matic review of the literature.  J 
Am Aca d Child Adolesc Psychiatry 47 : 21-31, 2008.  
 